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RESUMO 
A N-benzilpiperazina (BZP) pertence a um grupo compostos psicoativos sintéticos 
derivados da piperazina que surgiram no mercado ilícito nos últimos 20 anos. Enquanto 
legal, a BZP era o principal constituinte ativo das “party pills” e usada popularmente como 
droga recreativa devido às suas propriedades estimulantes do tipo anfetamina, tendo sido 
vendida como uma alternativa legal e segura a estas substâncias ilícitas.  
A popularidade e o crescente consumo levaram ao aparecimento de casos de 
toxicidade o que, juntamente com resultados de estudos in vivo, potenciou a cessação do 
seu carácter legal e inclusão nas listas de substâncias psicoestimulantes controladas um 
pouco por todo o mundo. 
É conhecido que a BZP sofre metabolismo hepático via citocromo P450 (CYP) 
existindo poucos estudos publicados sobre a sua toxicocinética, nomeadamente o perfil 
de distribuição da BZP e metabolitos nos tecidos. Por outro lado, os estudos publicados 
evidenciam discrepâncias entre a toxicocinética em humanos e animais (ratos Sprague-
Dawley), nomeadamente no perfil metabólico (proporção relativa dos principais 
metabolitos) e no tipo de conjugados encontrados. Um estudo não publicado demonstra 
ainda disparidades entre as concentrações plasmáticas e teciduais da BZP e dos 
metabolitos maioritários. Além disso, a toxicocinética de todos os metabolitos sugeridos 
para esta substância não foi ainda explorada. 
De forma a avaliar a disposição da BZP e metabolitos foi desenvolvido e validado um 
método de cromatografia gasosa acoplada a espectrometria de massa (GC-MS) que 
permitisse a sua quantificação simultânea. O método demonstrou seletividade e 
capacidade de separação da BZP e dos seus metabolitos: benzilamina, piperazina, N-
benziletilenodiamina, 3-hidroxi-BZP (3-OH-BZP), 4-hidroxi-BZP (4-OH-BZP) e 4-hidroxi-3-
metoxi-BZP (4-OH-3-OCH3- BZP),). De acordo com os ensaios de validação, apresentou-
se linear entre 0 - 5.000 ng/mL (R2 > 0,99) exceto para a benzilamina (R2= 0,9878), com 
limites de deteção (LOD) e quantificação (LOQ) a variarem entre 2 - 5 ng/mL e 7,5 – 20 
ng/mL, respetivamente. A precisão, inter- e intra-day, (CV% entre 3,43 – 14,68), exatidão 
(100±15%) e eficiência da extração (100±20%) foram consideradas aceitáveis.  
A aplicabilidade deste método ao estudo da toxicocinética foi comprovada em 
amostras de plasma de ratinho provenientes de um ensaio toxicocinético. 
 
Palavras chave: BZP, metabolismo, gas chromatography-mass spectrometry, 
toxicocinética, ratinho. 
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ABSTRACT 
N-benzylpiperazine (BZP) has become popular among recreational users of drugs as 
the major active ingredient of “party pills” due to their stimulant and euphoric effects in 
order to improve energy, vitality and mental capacity. These pills were sold as a safe and 
legal alternative to amphetamines like methylenedioxymethamphetamine 
(MDMA,”ecstasy”).  
Previous studies demonstrated that BZP undergoes hepatic metabolism via 
cytochrome P450 (CYP). There are only a few published studies on its toxicokinetics, 
namely on the disposition of BZP and its metabolites in the body. Furthermore, the 
available toxicokinetic studies show discrepancies between humans and animals 
(Sprague-Dawley rats), namely in the main metabolite and type of conjugates found. On 
the other hand, in the literature there is only reference to an unpublished work about the 
disposition of BZP and its two main metabolites, 4-hydroxy-BZP (4-OH-BZP) and 3-
hydroxy-BZP (3-OH-BZP), in rats which reports a disparity in plasma and tissue 
concentrations of this drug and the kidneys as the tissue with the highest concentration of 
the drug. However, no study has been published which evaluates the toxicokinetics of all 
the metabolites proposed for this substance. 
In order to assess the toxicokinetics of BZP in mice a gas chromatography-mass 
spectrometry (GC-MS) method was developed and validated. The method demonstrated 
selectivity and ability to resolve all the compounds (BZP, 4-OH-BZP, 3-OH-BZP, 4-OH—
3-OCH3-BZP, benzylamine, piperazine and N-benzylethylenediamine). In the validation 
assays, the method is linear between 0 - 5,000 ng/mL (R2> 0.99, except for benzylamine) 
and the limits of detection (LOD) and quantification (LOQ) range between 2 – 5 ng/mL and 
7.5 – 20 ng/mL, respectively. The precision, inter- and intra-day (CV% between 3.43 and 
14.68%), accuracy (100 ± 15%), and extraction efficiency (100 ± 20%) were considered 
acceptable. 
The applicability of this method to study BZP toxicokinetics was demonstrated in mice 
plasma from the pilot toxicokinetic assay. 
 
 
 
 
Keywords: BZP, metabolism, gas chromatography-mass spectrometry, toxicokinetics, 
mice. 
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FRAMEWORK 
This thesis will be divided in the following three parts: 
 Part I – General introduction 
This section contains a review about BZP, since its development as a potential 
antihelminthic drug and the evaluation as an antidepressant until its use as a 
recreational drug of abuse due to its stimulant properties. The characteristics of 
its recreational use are also referred, namely the “target population”, patterns 
and motivations of use, and evolution of its legal status. Moreover, the in vivo 
and in vitro studies performed in order to understand its pharmacology, 
toxicology and toxicokinetics are also discussed. Finally, its clinical and/or 
forensic analysis is briefly addressed. 
 
 Part II – Scope and objectives of the thesis 
In this section the aims of this thesis will be presented and discussed. 
 
 Part III – Experimental 
This section will be divided into three chapters: 
Chapter 1: Materials and methods 
This chapter describes all the reagents, biological specimens and techniques 
used to perform the development and validation of a gas chromatography-mass 
spectrometry (GC-MS) method and the pilot pharmacokinetic study of BZP in 
male Charles-River CD1 mice after a single intraperitoneal (i.p.) administration 
of 20 mg/kg and 50 mg/kg BZP (in saline). The method was developed and 
validated for the detection and quantitation of BZP and its identified metabolites 
(3-OH-BZP, 4-OH-BZP, 4-hydroxy-3-methoxy-BZP, piperazine, N-
benzylethylenediamine and benzylamine) in human plasma. 
Chapter 2: Results and discussion 
In this chapter the results obtained both during the validation of the GC-MS 
method and the pharmacokinetic study are presented and discussed. 
Chapter 3: Conclusions and future perspectives  
This chapter presents the final conclusions resulting from the experimental work 
and future perspectives. 
 
 Part IV - References 
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1.1. “Legal highs” and the emergence of piperazine derivatives 
 
Drug use remains a global problem and, over the years, there have been an 
emergence on new unregulated psychoactive compounds. These substances are known 
and marketed as “legal highs” or “herbal highs” and include a wide variety of natural 
(herbal), semisynthetic and synthetic substances which are designed to circumvent drug 
controls and mimic psychoactive effects of illicit drugs. “Legal highs” are available in a 
variety of formulations and are mainly purchased on internet websites or from street 
retailers (smart shops or head shops) (1, 2). These substances have experienced a rapid 
increase in popularity mostly attributed to aggressive web-based marketing (2, 3) but also 
to associations with street illegal drugs (e.g. names and symbols/logos) (4).  
The “legal high” market has a singular characteristic because after a ban of a particular 
substance, novel compounds quickly appear (in order to evade the law), and are 
advertised as being better than the previous ones (2, 5). It should be noted that the vast 
majority of these novel drugs have not been tested for their safety (lack of 
pharmacological and toxicological information) and, as they are not covered by any drug 
legislation or control, the potential health implications of their use are largely unknown and 
difficult to predict (2, 6, 7). The use of these products is normally based only in other 
users’ opinions (2, 3) and on the market advertisement, which, usually, doesn’t refer the 
presence of psychoactive compounds on the list of ingredients (1, 3, 8), adverse effects or 
provide safety information like contraindications and possible drug-drug interactions (2, 3, 
9). In addition, “legal highs” are frequently advertised as “air fresheners”, “herbal 
incenses”, “bath salts”, “plant fertilizers” and “not for human consumption” (1, 2, 10). 
Besides, it is still reported the inconsistency and lack of homogeneity in the composition of 
some “legal highs” sold over the internet (e.g., over time and between products sold by 
different suppliers with the same name) (8, 11, 12) and, on the other hand, some products 
sold as “legal” in fact contain substances already under control (11, 12), which increases 
the risk associated with the acquisition and use of such products.  
Most of these substances have gain popularity within the “rave” party scene 
(recreational drugs) among young people as alternatives to illicit drugs (7, 13). Among 
such recreational drugs, piperazine derivatives emerged during 1990s as a completely 
new class of designer drugs and safe and legal alternatives to amphetamines (7). The first 
medical use of piperazine compounds was as antihelminthic agents, in 1950s, for the 
treatment of human and animal worm infections. After that, several compounds with 
distinct pharmacological activities appeared on the market containing the piperazine 
Part I: General introduction 
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moiety, namely sildenafil and vardenafil (erectile dysfunction drugs), trazodone and 
nefazodone (antidepressant drugs) and, clozapine and olanzapine (antipsychotic drugs) 
(14). 
The piperazine derivatives have shown to possess psychoactive properties and were 
promoted as recreational drugs. According to their chemical structure, they can be divided 
into two groups: the benzyl- and the phenylpiperazines. The most common 
benzylpiperazines are the N-benzylpiperazine (BZP) and 1-(3,4-
methylenedioxybenzyl)piperazine (MDBP)); as phenylpiperazines became popular the 1-
(3-trifluoromethylphenyl)piperazine (TFMPP), the 1-(3-chlorophenyl)piperazine (mCPP),  
the 1-(4-methoxyphenyl)piperazine (MeOPP), the 1-(4-chlorophenyl)piperazine (pCPP) 
and, the 1-(4-fluorophenyl)piperazine (pFPP) (table 1) (15-18). These compounds were 
promoted and sold, particularly via Internet websites, as free bases or salt (19), mainly as 
capsules, pills, tablets, and powders (17, 20). They were sold as legal alternatives to 
amphetamines (generally blends of piperazines) but also in tablets sold as 
methylenedioxymethamphetamine (MDMA; ecstasy) or amphetamine (17, 21). The 
presence of piperazines were also reported in formulations of other drugs of abuse, 
namely ecstasy and cocaine (17). Due to its legal status and possibility of legitimate 
promotion, the spread potential of such substances is greater than for controlled 
substances (21). A survey in UK, by Davies et al. (2010) where 26 “legal highs” were 
purchased once a month over 6 months (January 2009 – June 2009), from five different 
internet sites in UK, showed that piperazines were the most common seen active product 
in the tablets purchased. 
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Table 1:  Principal piperazine derivatives used as recreational drugs. 
Name Abbreviation Structure 
1-benzylpiperazine BZP 
 
1-(3,4-methylenedioxy)benzylpiperazine MDBP 
 
1-(3-trifluoromethylphenyl)piperazine  TFMPP 
 
1-(3-chlorophenyl)piperazine  mCPP   
1-(4-methoxyphenyl)piperazine MeOPP 
 
1-(4-chlorophenyl)piperazine  pCPP  
 
1-(4-fluorophenyl)piperazine  pFPP  
 
 
1.2.  BZP: an overview 
1.2.1. BZP development and therapeutic relevance 
BZP was initially called and marketed over the internet and by some retailers as a 
“natural” product (“pepper extract” and/or “herbal high”) because of the structural similarity 
with piperidine, a component of the black pepper (“Piper nigrum”) despite its synthetic 
origin (21, 22).  
BZP was first developed, in 1944, as a potential antihelminthic agent for livestock by 
Wellcome Research Laboratories in the UK. However, because of its lack of efficacy 
compared with piperazine and side-effects (namely, seizures in mammals), it was never 
used for that purpose (20, 22). Later, in the 1970s, it was evaluated, by the same 
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laboratories, as a potential antidepressant agent due to its ability to reverse the sedative 
effects of tetrabenazine (dopamine depleting agent used for the treatment of involuntary 
hyperkinetic movement disorders such as Huntington’s Disease) in rats and mice (23, 24). 
However it was never marketed as an antidepressant possibly due to its similarities with 
amphetamines as hyperactivity and stereotypic behavior were observed after its 
administration to animals (22, 25). Such amphetamine-like effects, both subjective and 
physiological, were corroborated by in vivo studies in humans suggesting that BZP 
possess approximately 10% the potency of dexamphetamine (26, 27). The results of 
those investigations lead, for the first time, to the recommendation that BZP should be 
under the same regulatory measures applied to amphetamines due to its potential of 
abuse (26). In the 1980s, despite the previous findings and warnings, a derivative of BZP, 
N-benzyl-piperazine-picolinyl fumarate (also known as piberaline or EGYT-475) was 
developed by researchers at the Semmelweis University of Medicine in Hungary as an 
antidepressant (28, 29). EGYT-475 was manufactured and marketed as Trebilet® but the 
amphetamine-like properties of BZP made it unsuitable for therapeutic purposes (22, 24) 
and it was withdrawn following  phase II clinical trials (28). Later, it was discovered in in 
vitro studies that EGYT-475 was a pro-drug and that BZP (EGYT-2760) was the active 
metabolite responsible for its antidepressant properties (22, 28, 30). Literature, also refers 
that, later, befuraline (DIV-145; 1-benzofuran-2-yl(4-benzylpiperazin-1-yl)methanone), 
another BZP pro-drug, was developed and trialled as an antidepressant (figure 1). This 
compound showed effectiveness similar to imipramine with fewer side effects however, 
after phase II clinical trials the clinical research appears to have been discontinued (31). In 
conclusion, there are no licensed medical products containing BZP in the European Union 
and it is assumed that this substance has no therapeutic value (4). 
 
Figure 1: BZP (a) and its pro-drugs: EGYT-475 (b) and DIV-145 (c). 
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1.2.2. Physicochemical description and synthesis 
BZP, also known as 1-benzyl-1,4-diazacyclohexane or N-benzylpiperazine, is a 
diamine with no stereoisomers (4). The substance is available as a freebase or as 
hydrochloride salt (BZP.2HCL). As a free base (CAS: 2759-28-6)  it has a molecular 
formula of C11H16N2 and a molecular weight of 176.26 g/mol, and the hydrochloride salt 
(CAS: 5321-63-1) has a molecular formula of C11H16N2.2HCl and a molecular weight of 
249.19 g/mol (21, 28). 
The base form is a pale, slightly yellowish-green viscous liquid (4, 28) which presents 
an acidity constant (pKa) of 9.02 (20ºC) (28) and is corrosive. The hydrochloride salt is a 
white solid highly soluble in water, irritant to eyes, respiratory system and skin (4, 28). 
BZP is readily synthesized by the reaction of piperazine monohydrochloride and benzyl 
chloride, both easily available chemicals. This synthesis is significantly easier compared 
to other drugs such as amphetamine or ecstasy, and it seems that dibenzylpiperazine 
(DBZP) may be formed during the reaction as an impurity (4, 21). 
 
1.2.3.  BZP as a recreational drug 
1.2.3.1.  “Legal status” and evolution of the market  
In the 1970s and 1980s several studies showed that BZP has a stimulant 
amphetamine-like effect and in the 1990s the drug became popular as a recreational drug, 
being the major active ingredient of “party pills”  (22, 31). The abuse of BZP was first 
described in the USA in 1996, in California, (31, 32) although, its use remained minimal 
until the end of the 90s when BZP started to spread particularly among youth as a legal 
rave/party drug (31), particularly due to its promotion as “legal”, “natural” and “safe” (33). 
In fact, the promotion as “herbal pills” was perceived, particularly among youth, as a 
weaker and safer product due to its herbal origin unlike other synthetic “real drugs” (34). 
Besides the use as a recreational drug, it was also described the use of BZP as a doping 
agent in the field of horse racing (31) and by athletes (31, 35), where it is prohibited since 
January 1st, 2007, by the World Anti-Doping Agency (WADA) (36).  
Although being popular in many countries including the USA, Australia, Sweden, 
Japan, South Africa and Bulgaria, the drug only developed a significant market as a legal 
drug in New Zealand since 2000 until 2008, as the main psychoactive constituent of “party 
pills” or “BZP-party pills” (37), also known as “piperazine party pills” (PPPs), “herbal highs” 
or “social tonics” (6). In fact, in New Zealand there were over 120 brands of party pills 
(33), and, in 2005, was estimated that approximately 150,000 doses of party pills were 
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sold each month (38). According to literature, the New Zealand entrepreneur Matt 
Bowden, a former methamphetamine addict, was responsible for the introduction of party 
pills in the market, in 1999. In fact, Matt Bowden promoted BZP as a safer and legal 
alternative to illicit drugs, and referred a harm minimization role to this substance helping 
methamphetamine addicts to overcome their addiction (31). Until 2008 this substance was 
legal in New Zealand and, at this time it was estimated that the party pill industry was 
worth NZ$50 million (approximately 27 million euros) per year (37), with the prevalence of 
the use of BZP exceeding the use of any other illicit drug aside from cannabis, according 
to several performed surveys (31).  
Until 2005 there were no legal measures to control BZP, although, in 2005, following a 
recommendation from the Expert Advisory Committee on Drugs (EACD), BZP was the 
first substance to be classified as a “restricted substance” by the Misuse of Drugs 
Amendment Act 2005 (MDAA). At this point, BZP was made illegal to sell and supply to 
minors of 18 years old, and it was also prohibited the distribution of free samples besides 
television and print advertisement. Later, after the review of the epidemiologic and 
pharmacotoxicologic evidences, it was determined that BZP constituted a “moderate risk” 
and, on April 1st 2008, BZP and other related piperazines were reclassified as Class C1 
(similar to cannabis) and made ilegal to manufacture, import, export, supply, sell, and 
consume by the MDAA 1975 (31, 37). It is referred that other legal drugs, such as 1,3-
dimethylamylamine (DMAA) (37, 39), mephedrone and diphenylprolinol (D2PM) have 
taken much of the party pill market in this country (5). 
Similar to what happened in New Zealand, BZP started to be placed under control 
around the world, namely in the USA (since 2002), Australia and Japan (since 2006) (37). 
The size of the BZP market beyond New Zealand is less known, being reported 
sporadic seizures of BZP-party pills in the European Union (37), where it was first noted 
as a drug of abuse in Sweden in 1999 (40). At this time, BZP was added to the “Early 
Warning System”, a system designed to monitor new potential drugs of abuse (31). 
However, its widespread as a recreational drug in Europe only occurred in the second half 
of 2004 (4), and there has been an increase in the number of notifications to the European 
Monitoring Centre for Drugs and Drug Addiction (EMCDDA) and Europol relating to it by 
the end of 2006 (41). Between 2005 and 2007, formulations with BZP, mainly tablets and 
capsules, were extensively sold in smart shops, through websites and even in music 
festivals (42). During this period, despite the lack of control, seizures of BZP in powder, 
capsule or tablets were reported in 13 EU Member States (including Belgium, Denmark, 
Finland, France, Germany, Greece, Ireland, Malta, the Netherlands, Portugal, Spain, 
Sweden and the United Kingdom) and in Norway (4). The United Kingdom and Sweden 
were the two countries with the largest number and size of seizures (4, 41). Among tablets 
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seized the “Mitsubishi” and “Smiley Face” design were common, which may explain the 
BZP seizures before any regulation and the probable sale and acquisition of BZP, at least 
in part, as ecstasy (4). In fact, there was reported the acquisition of pills as being ecstasy 
pills when, in fact, they contained BZP (43). 
The growing concerns around this psychoactive substance led to a formal request for 
risk assessment in 2007 (41), despite some Member States (Belgium, Denmark, Greece, 
Malta and Sweden) already control BZP under drug control measures, Spain and the 
Netherlands regulate BZP under medicine-related legislation, and, at this time, in Ireland 
the sales were proihibited to the under 18 years (41). The BZP risk assessment reported 
the lack of information on the pharmacological and toxicological effects of such substance 
in humans, its activity as a central nervous system stimulant (CNS), and the possible 
interindividual variability in the expression of its toxicity due to genetic polymorphisms in 
metabolizing enzymes and interactions with other drugs. Consequently, it was 
recommended the establishement of appropriate control measures in the Member States 
(4). Later, in March, 2008 it was published the Decision of the Council of Europe that all 
Member States should apply to BZP control measures, accordingly to national legislation 
and the reduced risks known until date, within one year (42). 
Since this decision the availability of BZP in Europe appears to have decreased, 
despite some Member States continue to report its availability in 2009 and 2010 (figure 2) 
(1, 44). In fact, some works reported the presence of BZP and TFMPP, already under 
control, in legal highs sold by UK online legal highs retailers (8, 11). Furthermore, the 
combination of different substances in powders and tablets, and also the combination of 
BZP and other piperazines with other well-known drugs, such as amphetamine and 
ecstasy, is partly responsible for the increasing dificulty in the interpretation of the 
seizures (1). 
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Figure 2: Main groups of psychoactive substances notified by the European early-warning system (44).  
 
In Portugal, the first news about this recreational drug are from June 2006, although it 
has not been found any information about specific cases of seizures in our country. Thus, 
in June 2nd, 2006,  the “Jornal de Notícias” published online about the possibility of BZP to 
be synthesized from a medical substance available for the treatment of intestinal parasitic 
infections (www.jn.pt/PaginaInicial/Interior.aspx?content_id=675149). Later, in 2009, BZP 
integrated the controlled substances in accordance with the legal requirements applicable 
to trafficking and consumption of narcotic drugs and psychotropic substances approved by 
Decree-Law 15/93 de 22 of January, through Law No. 18/2009 , May 11, that proceeds to 
the 16th amendment of cited Decree-Law. BZP was then added to Table II-A being 
subject to the same control measures of other well-known illicit substances, including 
GHB, ecstasy, mescaline, lysergic acid diethylamide (LSD) and psilocybin (45). 
 
1.2.3.2. Patterns, prevalence and motivations of use 
Due to its legal widespread market in New Zealand, most of the knowledge concerning 
the use of BZP-party pills comes from this country. BZP is commonly swallowed in 
capsule or tablet form, although it is also reported the snorting of the powder as well as its 
mixture in drinks or swallow wrapped in cigarette paper (“hummer”) (34, 46, 47) and the 
intravenous (i.v.) use, in an attempt to a faster onset of the action. The i.v. administration 
of BZP was reported by the users as being painful due to the alkalinity of the solution 
(pH≥12) (20). 
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BZP was sold and consumed in products more commonly known as “Legal X”, “Herbal 
ecstasy”, “Legal E” and “A2” (4, 48), and was marketed under different brand names (for 
example, “P.E.P. pills”, “Jump”, “Euphoria”, “Rapture”, “Frenzy”, and “Charge”) (4, 37, 49).  
With the increasing popularity of party pills, the combination of BZP with other 
psychoactive substances, such as other piperazines (mainly, TFMPP, mCPP and 
MeOPP), increased (29, 38, 50), in addition to other ingredients like caffeine, herbal 
extracts, amino acid and electrolyte blends, in order to enhance its positive effects (29, 46, 
51) or diminish the side effects (for example, l-tyrosine as a precursor of dopamine in 
order to ameliorate any dopamine depletion due to the consumption of such pills) (29). 
The combination of BZP with TFMPP was the most popular combination of piperazines in 
party pills, and is reported by the drug users that the consumption of this combination is 
an attempt to mimic the MDMA effects (17, 19, 51, 52). In fact, the effects of TFMPP in 
the release of serotonin (5-HT) are suggested as being responsible for the hallucinogenic 
effects attributable to pills containing such mixture in addition to the stimulant and 
euphoric proprieties of BZP (52, 53). Furthermore, in mice, the combination 
(BZP+TFMPP) has been shown to have similar effects to MDMA in the release of 
dopamine (DA) and 5-HT (52). In these pills the ratio of BZP to TFMPP can range from 
2:1 to 10:1 (30, 54). It is still referred its combination with other illicit substances such as 
amphetamine, ecstasy, cocaine and ketamine, to enhance its stimulant and euphoric 
effects (17, 21). Furthermore, nevertheless the advertising from the retailers to avoid the 
combination of party pills with alcohol, medicines and other drugs (46, 47, 55), surveys 
conducted in New Zealand found that most party pills users consumed it in combination 
with other psychoactive substances, particularly alcohol, ecstasy, cannabis, 
amphetamines and nitrous oxide (46, 47, 49). Such surveys also revealed that the 
combinations of party pills with other substances often had specific roles, such as: (i) 
increase or extend the stimulant effects; (ii) allow a greater intake of alcohol since it is 
reported that party pills increase sobriety (46, 47); (iii) allow to deal with the negative 
effects of party pills (for example, cannabis to relax, stimulate appetite and sleep) (46). 
Besides cannabis, tobacco, and alcohol the so-called “recovery pills” are also used with 
this purpose. “Recovery pills” contain 5-hydroxytryptophan (5-HTP) and have been sold, 
sometimes in the same packs, and marketed as being able to reduce the adverse effects 
of party pills as it is converted to 5-HT in the brain (47, 49). Some authors also suggest 
that as BZP and 5-HTP increase the levels of 5-HT it may increase the risk of adverse 
side effects as occurs with ecstasy (49). 
The growing popularity as well as the emergence of several brands was accompanied 
by an increase in the amount of BZP content (30, 33, 55), with the typical dose of BZP 
ranging between 50 and 200 mg (29, 30, 49). There are also references to party pills 
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containing higher quantities, up to 1000 mg, though it was not a common scenario (20, 
33). Some differences between what was labeled on the packages have been detected, 
both in the qualitative (piperazines present) and quantitative content (30, 56). 
According to surveys conducted in New Zealand, the average amount of party pills 
consumed per occasion is approximately 2/3, although there are reports of consumption 
of 8 or more pills (34, 46, 47), exceeding what was usually recommended by 
manufacturers (“2, wait 2 h, then another 2 if tolerated”) (30). A survey (n=189) performed 
by Wilkins et al. (2008), revealed that the amounts of piperazine (BZP/TFMPP) taken on 
an occasion of greatest use ranged between 43-2500 mg, with the highest amount of 
participants having consumed between 100-500 mg. As the amount of BZP in party pills 
varies considerably between brands, the amount of BZP and other piperazines consumed 
depends not only on the number of party pills taken but also the strength of such pills (49). 
This high consumption may result in the exacerbation of toxicity and is in line with data 
from hospitalizations due to the intake of party pills (20). Furthermore, it seems that this 
high consumption may be associated to the lack of the desired effect or time that is 
needed to those effects occur (20, 46), as well as due to the promotion of such products 
as “herbal” and legal which leads the user to underestimate the strength of the products 
(33, 57). The amount of party pills consumed also seemed to depend on the places and 
context of use as well as the side negative effects (“hang-over”) already experienced by 
consumers (46). In fact, adverse effects are reported as one of the main reasons leading 
to the decrease in the use of party pills, in addition to changes in lifestyle, and seasonal 
variations related to the recreational environments in which these products are generally 
consumed (46, 47). 
According to the studies performed in New Zealand the use of legal party pills was 
highest amongst youth and young adults (46, 47). A household survey, in 2006, revealed 
that, out of 2010 individuals, aged between 15 and 45 years old, the prevalence of use 
was higher among those aged 18-29 years, with almost 50% (48.8%) of respondents 
between 20-24 years having ever tried party pills (figure 3) (47). This survey, like others, 
showed that in almost all age groups the use was greater among males than females (34, 
46, 47).  
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Figure 3: Prevalence of “ever tried” party pills by age and gender (47).  
 
In addition, BZP-party pills users include both users of illicit drugs and legal substances 
from different social classes, being used in particular by high school students and 
university employees as well as by part- or full-time workers (34, 46, 47). Thus, unlike 
what occurs with the regular consumers of other type of drugs, namely illicit drugs, BZP-
party pills consumers did not seem to arise from groups socially and/or economically 
marginalized (46). 
The majority of the BZP-party pills users declared using BZP as a recreational drug 
due to its stimulant proprieties (increased confidence, talkativeness, euphoria, vigor and 
activity, and enhanced socialization) (2, 46, 47), mainly at night and weekends at dance 
parties or “raves” (22, 46). The studies also highlighted the similarities between the use of 
BZP-party pills and ecstasy, particularly, the use of other drugs and extended periods of 
dancing in heated environments (37, 46). Besides the recreational use of such drug, a 
more functional use is also reported as a means of increasing alertness and 
physical/mental performance among students and workers (such as shift workers and 
truck drivers) (37, 46). Other less common uses were also reported as for example, the 
use by young females as an appetite suppressant for weight loss (47). 
 
1.2.3.2.1. Impact of the legal status on the consumption of BZP 
Studies performed in New Zealand revealed that the legal status of BZP affected its 
use, particularly among young people (47, 57). In fact, a study performed by Sheridan and 
Butler (2010), in New Zealand, showed that because BZP-party pills were legal, the users 
(n=58, aged between 17-23 years) had the perception that they were safe compared with 
illicit substances. Furthermore, many believed that the legality of these products 
safeguard their quality, unaware that there were no controls in the manufacturing process. 
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The presence of labels in the products also carried the perception of quality and purity and 
confidence that they were consuming exactly what they bought, despite the lack of any 
kind of assessment to which the products were subjected in order to prove the veracity of 
the information on the label. With respect to the strength of such pills, many respondents 
said that they expected that as these products were legal the psychoactive effects were 
moderate. Additionally, the legalility provided an easier access to these products and the 
lack of criminal behaviour unlike what happens with illicit drugs (57). 
In conclusion, the legal status conveyed the perception of quality, safety, lack of 
criminal activity, and expection that the psychoactive effects were relatively mild. 
Furthermore, being legal these products were widely available and socially 
accepted/legitimate to use (57). All these factors with their promotion as a legal and safe 
alternative to other drugs were motivating factors for BZP-party pills consumption (57). 
According to that, BZP-party pills, while legal, may acted both as a “gateway” to illicit 
substances or as a harm reduction “player” with illegal drug users taking BZP instead of 
illicit drugs (29, 37, 47). Nevertheless, the real impact of BZP-party pills legality and 
prohibition in the consumption of illegal drugs is not conclusive (37, 58) and might be both 
positive and negative. In fact, on one hand its criminalization appears to have led to its 
decreased availability and consumption (31, 58, 59) both among general population and 
frequent drug users (58), but, on the other hand, its ban from the legal market and as a 
legal alternative to other drugs might conduct to a shift from BZP use to illegal drugs, to 
other legal substances with unknown toxicity and/or to an increased criminalization around 
BZP-party pills (37, 60, 61). 
Apart from BZP criminalization, other factors mentioned by users as being important 
reasons for stopping BZP use both before and after the criminalization were the hang-over 
effects and physical health reasons (47, 58). 
 
1.2.3.3. Health issues related to BZP use 
Despite the misconception that BZP-party pills are safe, there are a number of case 
reports and clinical evidence supporting its toxicity, which is expected to be due to the 
similarities of this substance with amphetamines (17). Again, due to the more expressive 
market of this substance, the clinical experience of piperazines toxicity in New Zealand is 
probably the greatest (39, 48). The adverse physical symptoms most frequently reported 
by users are: insomnia, headaches, and nauseas (31, 47). Other negative effects reported 
include: dizziness, mood swings, agitation, strange thoughts, tremor, dry mouth, 
diaphoresis, dehydration, urine retention, xerostomia, tachycardia, bruxism and trismus, 
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mydriasis, loss of appetite, and tiredness, some of which appeared to persist for more 
than 24 h after ingestion (20, 46, 47). 
Some more serious adverse effects have also been reported namely: metabolic and 
respiratory acidosis, hyponatremia, toxic seizures (20, 62), acute paranoid psychosis (32), 
dissociative states (43), and exacerbation of mental illness (63), hyperthermia, 
rabdomyolysis, disseminated intravascular coagulation, acute renal injury and multiple 
organ failure (13, 33, 64, 65). Overall, according to data available from clinical and users 
reports, most of the symptoms are characteristic of a sympathomimetic toxidrome similar 
to amphetamines and other sympathomimetics (28, 66).  
BZP had also been related to fatalities and detected in post mortem samples (40, 66-
69), although the role of BZP in the poisonings and deaths reported is difficult to evaluate 
due to its common use in combination with other substances (17, 37). Secondly, the fact 
that many clinicians were not aware of this substance; the similarities in the patterns of 
distribution and pharmacological effects with amphetamines; and the absence of 
screening tests for BZP and other new designer drugs in clinical practice can lead to the 
understimation of the role of such substances in poisonings (17). Furthermore, despite 
being accepted that higher plasma levels of BZP are related to an increased incidence of 
more severe side effects, such as seizures (33), serum or urine concentrations may not 
correlate with the severity of clinical symptoms. In fact, toxicity seems to be unpredictable 
with some users expressing significant toxic effects even after the ingestion of 
“recommended” doses, suggesting the possibility of a narrow safety margin and 
interindividual pharmacokinetic variation due to genetic polymorphisms and/or drug 
interactions (13, 28, 33). Furthermore, the environment of the rave party (heat, increased 
physical activity, lack of sleep, dehydration, excessive fluid ingestion, and co-ingestion of 
other psychoactive substances) also contribute to the toxicity associated with BZP-party 
pills intake (13). Women also seem to be at a higher risk due to their smaller body size 
compared to men (33, 49). 
There is limited information on the long-term effects of BZP intake, namley its potential 
to induce addiction, tolerance or organic sequelae (28). 
There are no specific treatment guidelines to BZP toxicity and the management of 
patients consists in their stabilization and supportive and symptomatic care. Depending on 
the symptoms, the management may include the correction of hyponatremia, 
hyperthermia, tachycardia, dehydration, hypertension, acid-base disturbances, and 
monitor of renal, muscular, cardiovascular and hepatic functions. The treatment of 
seizures and psychotic states may require the use of benzodiazepines and antipsychotics 
(20, 28). 
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1.2.4. Pharmacodynamics 
1.2.4.1. Neuropharmacology 
During the assessment of piberaline, Magyar et al. (1986) found that its metabolite, 
BZP, had the ability to potentiate the release of 3H-noradrenaline (3H-NA) from rabbit 
pulmonary artery, being this effect inhibited by the administration of 1-NA and clonidine, 
preferential agonists of presynaptic α2-adrenoreceptors (70). The first effects of BZP on 
serotoninergic neurotransmission are also reported to the pharmacological assessment of 
piberaline and it was concluded, during these studies, that BZP blocks the reuptake of 5-
HT in rats and has 5-HT1 receptor agonistic effects, these the mechanisms responsible for 
their central serotoninomimetic action. Those studies have also shown that BZP had no 
effect on 5-HT2 receptors (66, 71). Some other studies also suggested that BZP has 5-HT 
antagonistic properties due to its ability to antagonize 5-HT-induced contractions of rat 
stomach fundus, and partial agonistic properties as it induced hyperthermia in rats, effect 
reversed by cyproheptadine, a 5-HT antagonist (24). It was suggested that those effects 
on serotoninergic neurotransmission may be responsible for, at least, some of BZPs side 
effects, such as headaches and nausea (51).  
In a more recent work, Baumann et al (2004) evaluated the neurochemical effects of 
BZP, MDMA, and TFMPP on transporter-mediated efflux of [3H]5-HT (serotonin 
transporter (SERT) substrate) and [3H]MPP+ (DA transporter (DAT) substrate) in rat 
synaptossomes. Additionally, they evaluated the effects of such drugs on the extracellular 
levels of 5-HT and DA using in vivo microdialysis in rats. According to their in vitro 
findings, BZP evokes DAT release of [3H]MPP+ but showed no effect on the release of 
[3H]5-HT mediated by SERT (unlike MDMA and TFMPP). Furthermore, the effect of BZP 
on DA release was antagonized by low doses of DAT selective blocker. The in vivo 
studies showed that BZP has the ability to elevate the extracellular levels of both DA and 
5-HT in a dose-dependent fashion, being prevalent the effects over DA, and about 3-fold 
less potent than MDMA.The mixture of BZP and TFMPP (1:1 ratio) resulted in dramatic 
dose-related increases in dialysate DA and 5-HT, suggesting a synergistic effect on DA 
(at the higher dose 10 mg/kg) and additive effect on 5-HT. Such effects on monoamines 
neurotransmission may explain the MDMA-like properties reported to the combination of 
such piperazines as they mimic the known molecular mechanism of MDMA. In vitro no 
interactions between the two drugs were noted, suggesting a possible pharmacokinetic 
nature for the in vivo synergism reported (52, 72). Lastly, Nagai et al (2007), using rat 
brain synaptossomes showed that BZP strongly inhibits the reuptake of DA and NA and 
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has a smaller effect on 5-HT reuptake. Furthermore, BZP also showed a monoamine-
releasing activity, particularly on DA and NA (73).  
In conclusion, similar to what occurs for other drugs of abuse, in vitro and in vivo 
studies have demonstrated that BZP interferes with monoaminergic neurotransmission, 
both inhibiting the reuptake and stimulating the release of DA, 5-HT and NA, 
predominating the effects on dopaminergic neurotransmission. 
 
1.2.4.2. Behavioral and physiological studies in animals 
The first behavioral effects of BZP were reported during the assessment as an 
antidepressant in rats. The studies showed that BZP induces hyperactivity, involuntary 
head movements and reduces the reaction time in shock avoidance studies, similar to 
dexamphetamine (26). More recent works, in mice and rats, corroborated these first 
findings highlighting the powerful locomotor stimulant effects of BZP (i.p. administrations 
with doses ranging from 5 mg/kg to 100 mg/kg), showing that this compound produces a 
dose-dependent increase in ambulation and stereotypy (72, 74-76). The only available 
studies with primates (rhesus monkeys) also reported behavioral effects, such as 
hyperactivity, involuntary head movements, jaw chattering, bizarre body postures, and “fly 
catching” (24).  
The assessment of the effect derived from chronic exposure showed that repeated 
exposure to BZP (20 mg/kg) induces sensitization and cross-sensitization to 
methamphetamine, measured as increases in hyperactivity (75). These acute and 
sensitized behavioral responses that have been related to increases in the dopaminergic 
neurotransmission, as increases in dialysate levels of DA were dose-dependent and 
shown a positive correlation with increases in locomotor activity and stereotypical 
movements (72, 75). Furthermore, stereotypy and hyperactivity have been related to 
increases in nigrostriatal and mesolimbic dopaminergic neurotransmission, respectively. 
Changes and adaptations in the dopaminergic neurotransmission induced by chronic 
exposition to BZP were also suggested has being implicated in the sensitization and 
cross-sensitization, similar to what have been suggested to other stimulant drugs (75). 
Thus, BZP may induce neuroadaptations that sensitize users to other drugs and 
potentially act as a “gateway drug” to other more harmful drugs (75). 
The rewarding properties of BZP were evaluated using self-administration (24), 
discriminative (24, 74), and place preference methods (77). Fantegrossi et al (2005) 
showed that BZP induces intravenous self-administration in animals (rhesus monkeys) 
trained to self-administer cocaine and possesses discriminative responses similar to 
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amphetamine (24). In rats, BZP induced conditioned place preference in a dose-
dependent manner (77) and, in mice, induced MDMA-like discriminative stimulus without 
inducing head twitch behavior (used to assess hallucinogen-like actions) (74). DA 
neurotransmission at the mesolimbic system has been implicated in the rewarding 
properties of several other psychoactive drugs (25) and, in fact, during Meririnne et al 
(2006) experiments, a DA D1-like receptor antagonist attenuated BZP-induced place 
preference. Furthermore, the involvement of serotonergic system was also suggested as 
a 5-HT3 receptor antagonist also attenuated the BZP-induced place preference response 
(77). In conclusion, similar to other drugs of abuse, BZP induces conditioned place 
preference, showing discriminative stimulus properties similar to amphetamine and 
reinforcing effects similar to cocaine. These findings in animals corroborated previous 
evidence in humans that suggested that BZP has abuse liability. 
When assessing the similarities in acute effects on anxiety-related behavior between 
BZP (10 or 20 mg/kg) and methamphetamine (1 or 2 mg/kg) in hooded rats, it was not 
clear if the altered behavior of rats were due to an increased anxiety induced by the drug 
or to an increased stereotypy that interfered with the action of the drug (76). However, 
despite the little conclusive evidence for anxiogenic effects of BZP, its anxiogenic potential 
should not be overlooked as increased anxiety has been reported by BZP-party pills users 
(20, 47). 
Due to BZP similarities with other drugs possessing serotonergic and dopaminergic 
agonist properties about which is known to interfere with the normal neuronal 
development and produce cognitive and mood deficits (78), the possible long term effects 
resulting from the exposition to BZP during adolescence were also evaluated. A 
preliminary study performed by Aitchison and Hughes (2006) in rats evaluated the 
behavioral consequences following the administration of BZP (10 mg/kg/day, i.p.) during 
P45-P55 (equivalent of late human adolescence to early adulthood), with particularly 
attention to its anxiogenic potential and sex-related differences. From the results 
(decreased social interactions, responsiveness to brightness change, and emergence 
from the dark into the light) of this study it was suggested the possibility of BZP interferes 
with the development of anxiety-related mechanisms operated by 5-HT, resulting in 
increased levels of anxiety in adulthood. Yet, even due to more pronounced effects of 
BZP on dopaminergic system, it was also referred that the behavioral effects observed 
may be related to the depletion of DA and thus the decreased motor activity can be a 
result of BZP exposure (78). In fact, abnormal dopaminergic activity has been associated 
with deficits in motor control and aggressiveness. Additionally, a recent work assessed the 
long term effects (in the periods P78-81 and P117-120) resulting from the exposure to 
BZP (10 mg/kg/day, i.p.) and/or ethanol (2 g/kg/day, i.p.) during adolescence (P41-50), 
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and there were not find statistically significant differences between treated animals and 
controls (25). Nevertheless these non consistent results it was highlighted that BZP 
exposure, particularly during adolescence, can have long-term outcomes. 
In literature is also cited that BZP induces hyperthermia when administered to rats at 
an ambient temperature of 28ºC (79). This effect has been related with the action of 5-HT 
on the thermoregulatory centre within the hypothalamus, and is probably directly related 
with the dose and the room temperature as seen with other drugs with hyperthermic and 
hypothermic effects (80, 81) 
 
1.2.4.2.1. Combination with other substances 
Due to the frequent combination of BZP with other substances by users, the 
assessment of the effects of these combinations is essential to assess the safety of BZP, 
given that resembles the real context associated with their consumption. 
During the study of Baumann et al. (2004) it was noted that, in contrast with BZP, the 
mixture of BZP plus TFMPP (1:1) did not produced robust locomotor stimulation and, at 
the high dose (10 mg/kg, i.v.) the motor stimulant effects were suppressed with several 
rats developing seizures and ataxia. Despite the seizures were short-lived and all animals 
recovered completely, the dose which caused these effects (10 mg/kg BZP + 10 mg/kg 
TFMPP, i.v.) was only about three times higher than that required for the effects on 
monoaminergic neurotransmission were visible, which suggests a narrow window of 
safety. It has been suggested that the suppression of BZP psychomotor properties by 
TFMPP is due to its properties at a postsynaptic level on serotonergic neurotransmission   
(52, 72). 
The reinforcing properties of the mixture were also evaluated in rhesus monkeys and 
the reinforcing effects of BZP when combined with TFMPP were less pronounced than 
with BZP alone, decreasing with the increase in the concentration of TFMPP. In this same 
study, TFMPP alone had not discriminative nor self-administration properties. These 
results were in accordance with results observed with other hallucinogenic drugs, being 
suggested that agonistic action at 5-HT2c receptors suppresses dopaminergic activity at 
the mesolimbic system  (24). 
Perry (2008) also evaluated the long-term effects of the exposure to BZP in 
combination with alcohol during adolescence in rats without, however, showing 
statistically significant differences between the three groups (animals treated with BZP; 
BZP + ethanol; ethanol) (25). 
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1.2.4.3. Human studies 
Similarities between BZP and dexamphetamine were reported in humans (with no 
previous experience on amphetamines) in 1971 (Munro-Faure et al.) and 1973 (Bye et 
al.), with doses ranging from 20 to 100 mg (26, 27). Both compounds produced increases 
on heart rate and blood pressure (systolic and diastolic), pupillary dilatation (when 
administered as eye-drops), improvements in the test of auditory vigilance and stimulant 
activity. The stimulant activity was similar and only detected when volunteers received the 
highest doses tested, 100 mg BZP or 7.5 mg dexamphetamine (26, 66). Another study, 
performed by Campbell et al (1973) in former amphetamine-type addicts, compared the 
subjective and physiological effects of BZP (BZP hydrochloride, 100 mg), 
dexamphetamine (dexamphetamine sulphate, 10 mg) and a lactose control, in double 
blind conditions. Observations of pulse rate, blood pressure, pupil size, and mental/mood 
status were made and repeated at 1, 2 and 3 h after their administration. Both d-
amphetamine and BZP caused increases on pulse rate and blood pressure, as seen in 
previous studies. BZP also produced pupillary dilatation (not noted with d-amphetamine), 
sweating and flushing. The subjective effects were indistinguishable with both drugs being 
considered desirable, and BZP was scored by many better than d-amphetamine in terms 
of subjective drug liking. Overall, these studies concluded that BZP has a stimulant activity 
similar to d-amphetamine but an effective potency about 10-fold lower (19, 66). 
In a recent, randomized, double blind, placebo-controlled study, the physiological and 
subjective effects of BZP (200 mg in a single oral dose) were evaluated in 27 human 
females. It was again noted that BZP significantly increases blood pressure and heart rate 
and has stimulant effects, increasing euphoria, dysphoria (maybe related with a rebound 
effect), sociability and drug liking. A decrease in body temperature was also recorded after 
administration of BZP when compared to placebo, suggesting that the room temperature 
might not be high enough to induce hyperthermia (80). 
The cardiovascular effects have been attributed to the peripheral sympathomimetic 
action of BZP, while the stimulant and subjective effects are attributted to the stimulation 
of dopaminergic and serotonergic neurotransmission at a central level (30, 80). 
 
1.2.4.3.1. Combination with other substances 
The physiological and subjective effects of BZP (100 mg) in combination with TFMPP 
(30 mg) were also determined in human males. Similar to what was observed with BZP 
alone, the combination significantly increases blood pressure (both diastolic and systolic) 
and heart rate, without visible changes in body temperature. According to the subjective 
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rating scales, the combination has similarities with other commonly known stimulants 
producing dexamphetamine and MDMA-like effects, increasing dysphoria and self-
confidence (54, 81).  
Another randomized, double-blind, placebo-controlled study performed in New Zealand 
by Thompson et al. (2006) evaluated the safety of four treatments: (1) BZP+TFMPP (300 
mg/ 74 mg) and placebo;  BZP+TFMPP (300 mg/ 74 mg) and 57.6 g alcohol; (3) 
placebo and 57.6 g alcohol; and (4) double placebo. BZP and TFMPP were administered 
in two doses within a 2 h interval and the total amount of alcohol was ingested in six 
doses. The cardiovascular and psychological effects, delayed effects on sleep, adverse 
events and the effects on a driving performance test were evaluated for all groups under 
study. This study showed more reliability with the recreational use of party pills, not only 
due to the combination of piperazines but also for its combination with alcohol and the use 
of party pills commercially available instead of the compounds isolated. The study was 
stopped earlier when only 35 of the planned 64 subjects had been included in the trial due 
to the emergence of severe adverse effects (such as agitation, anxiety, hallucinations, 
vomiting, migraine, and insomnia). Those events were reported in 4/10 subjects who 
received the combination of piperazines, and in 3/7 subjects who received this 
combination and alcohol. Apart from these adverse effects, the combination of 
piperazines, with or without alcohol, caused marked increases on blood pressure, heart 
rate and difficulty in getting to sleep. BZP and TFMPP combined also resulted in 
significant improvements in the driving performance test even in combination with alcohol 
(alone affected negatively the driving performance). Overall, the results of this study 
showed that BZP+TFMPP alone or in combination with alcohol, even when consumed 
according to “manufacturer’s instructions”, carries a significant risk of severe adverse 
events (30). 
 
1.2.5. Toxicokinetics 
1.2.5.1. Metabolic pathways 
The toxicokinetics of BZP is not yet fully elucidated, in fact, there are few published 
information about its absorption and distribution, both in humans and animals.  
The metabolism of BZP was first studied by Staack et al. (2002) in Wistar rat urine after 
a single dose of 50 mg/kg by gastric intubation and the results were compared with 
human urine samples. According to the metabolites identified, it has been proposed that 
BZP undergoes hydroxylation and dealkylation as phase I reactions and has three 
metabolic targets: the aromatic ring, the benzyl carbon and the piperazine moiety. The 
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aromatic ring is altered by single aromatic hydroxylation to form 4-hydroxy-BZP (4-OH-
BZP; p-OH-BZP), 3-hydroxy-BZP (3-OH-BZP; m-OHBZP), and double aromatic 
hydroxylation followed by methylation to form 4-hydroxy-3-methoxy-BZP (4-OH-3-OCH3-
BZP). Furthermore, metabolic dealkylation at the benzyl carbon and piperazine moiety 
leads to the formation of piperazine, benzylamine and N-benzylethylenediamine (figure 4). 
From the dealkylation at the benzyl carbon it was also suggested the formation of 
benzaldehyde which can be further oxidized to benzoic acid; however, as benzoic acid is 
ubiquitous in rat urine, the formation of such a metabolite cannot be confirmed (71). The 
hydroxylated compounds can still enter phase II reactions being partially eliminated as 
sulfate or glucuronide conjugates (7, 71, 82). The first study on the toxicokinetics of BZP 
in humans, also suggested, according to mass spectra, the formation of BZP conjugates 
with sulfates (83). 
According to the metabolites identified the enzymes that have been proposed as being 
involved in BZP metabolism are: cytochrome P450 (CYP) which catalyzes phase I 
reactions (hydroxylations and dealkylations) (38, 53), catechol-O-methyl-transferase 
(COMT) that catalyzes the methylation of the dihydroxy metabolite (71, 84), 
sulfotransferase (SULT) and uridine diphosphate glucuronyltransferase (UDP-
glucuronosyltransferase; UGT) responsible for the formation of sulfate and glucuronide 
conjugates, respectively (85).  
In addition to the factors previously mentioned as possibly implied in BZP unpredictable 
toxicity (such as drug-drug interactions and environmental factors), the occurrence of 
genetic enzymatic polymorphisms may also contribute to its interindividual variability, as 
there are well known polymorphisms for the enzymes involved either in phase I 
(particularly CYP 2D6) and phase II (COMT, SULTs and UGTs) metabolic reactions (23, 
38).  
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Figure 4: Metabolic pathways of BZP proposed by Staack et al. (2002).  
The bold arrows represent the metabolic pathways suggested as being dominant. The compounds identified 
are: (1) BZP, (2) 4-OH-BZP, (3) 3-OH-BZP, (4) 4-OH-3-OCH3-BZP, (5) piperazine, (6) benzylamine, and (7) 
N-benzylethylenediamine (adapted from Staack et al., 2002). 
 
1.2.5.2. In vitro studies 
Considering that the dealkylation and hydroxylation pathways are dependent on the 
action of CYP enzymes, it was studied the involvement of five CYP isoforms (CYP 2D6, 
1A2, 3A4, 2C9, and 2C19) in BZP metabolism, using pooled human liver microsomes to 
minimize the effect of interindividual variability and selective inhibitors of specific CYP 
isoforms. This study showed that, when incubated with specific inhibitors of CYP 1A2, 
3A4, and 2D6 isoforms, the metabolism of BZP was significantly inhibited, highlighting the 
involvement of such isoenzymes in the hepatic metabolism of BZP in humans. The 
inhibition increased in the following order: CYP 2D6 (28%) < CYP 3A4 (54%) < CYP 1A2 
(74%). In contrast, the inhibitors of CYP 2C9 and 2C19 did not affect the metabolism of 
BZP (23, 86). The inhibition of metabolism by CYP 3A4 and 1A2 appeared to be 
concentration-dependent, but, in contrast, for CYP 2D6 the inhibition did not appeared to 
be dependent on the concentration of BZP (23).  
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1.2.5.3. In vivo studies 
1.2.5.3.1. Animals studies 
Tsutsumi et al (2006) studied the metabolism of BZP in Wistar rat by analyzing the 
excretion profile (within the first 48 h) of BZP and its major urinary metabolites (4-OH-BZP 
and 3-OH-BZP), following a single i.p. dose of 5 mg/kg BZP. The study showed that, 
within 48 h, approximately 25% of BZP was eliminated as 4-OH-BZP and only 2% as 3-
OH-BZP, and 6.7% dose of BZP was excreted unchanged (figure 5). Almost 50% of 
metabolites were eliminated as glucuronide conjugates, and lesser as sulfate conjugates. 
The 4-OH-BZP/3-OH-BZP increased with time suggesting a preference for the formation 
of the p-hydroxylated metabolite over time. The urinary peak of BZP was observed at 
about 4h post-dosing (undetectable 48 h post-dosing) while metabolites peaked 
approximately 8h post-dosing and were detectable up to 48 h post-dosing. In resume, 4-
OH-BZP was found as the main urinary BZP metabolite in rats corroborating what was 
reported by Staack et al (2002). After 48 h, approximately 33% of the dose administered 
was eliminated (about 20% unchanged and 80% as its main metabolites), unlike what was 
described by Staack et al (2002) where BZP was excreted mainly unchanged in urine 
(84). Despite these discordant results, given that the animals belong to same species 
(Wistar rat), it is necessary to take into consideration that the dosages and routes of 
administration were different. 
 
Figure 5: Urinary excretion profile of (●) BZP and its main metabolites: (■) 4-OH-BZP and (x) 3-OH-BZP after 
a single i.p. dose of 5mg/kg (84). 
 
An unpublished work made by Chou et al (2008) at University of Auckland with 
Sprague-Dawley rats, after a i.p. dose of 1 mg/kg, evaluated the tissue disposition of BZP 
and its main metabolites (4-OH-BZP and 3-OH-BZP) 30 and 60 minutes post-dosing. 
According to this work, BZP appears to be rapidly metabolized and distributed to tissues 
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with kidneys being the organ displaying the highest concentration of BZP and liver 
displaying the major concentrations of 3-OH-BZP and 4-OH-BZP (87). This explain, at 
least in part, the preliminary results reported by Cole (2011) which refers that BZP is 
extremely toxic to both liver and kidney cell lines as well as the symptoms of renal and 
hepatic failure reported in some of BZP users (88). 
Later, Wada et al. (2012) performed a study in order to evaluate the plasmatic profile of 
BZP and TFMPP in rat (Wistar), after a single i.p. sole or co-administration of 2 mg/kg of 
the drugs (figure 6). BZP was monitored in plasma for, at least, 480 min after 
administration (Limit of detection= 0.9 ng/mL). The toxicokinetic parameters are presented 
in table 2. 
 
Figure 6: Concentration-time plasmatic profile of BZP after a single 2 mg/kg i.p. administration alone or in 
combination with TFMPP (1:1) (89). 
Table 2: Toxicokinetic parameters for BZP (2 mg/kg, i.p.) in rat (Wistar) (89). 
 Rat pharmacokinetic study (mean ±SD, n=3) 
Parameter BZP 
K (min
-1
) 0.0037±0.0016 
V (L) 5.1±2.1 
AUC0-360 (min.mg/mL) 22±5.1 
Elimination half-life (t1/2) (min) 219±108 
Cl (L/min) 0.017±0.0038 
AUC, area under the curve; Cl, clearance; K, rate constant; SD, standard deviation; V, distribution volume. 
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1.2.5.3.2. Human studies 
The only available pharmacokinetic study in humans reported the plasma 
concentrations of BZP, 4-OH-BZP and 3-OH-BZP (the only metabolites detected in the 
study) over a 24h period (blood was collected at 0, 15, 30, 45, 60, 75, 90, 105, 120, 180, 
240, 300, 350, 480, and 1440 min) and evaluated its excretion in 24 h urine, after a single 
oral dose of 200mg (BZP.2HCl). In contrast to what was described in animal studies, 3-
OH-BZP concentrations were always higher than 4-OH-BZP concentrations showing that 
the m-hydroxylation is the main metabolic pathway in humans, and BZP was detected in 
plasma for up 24h following the oral administration (limit of quantification of 5 ng/mL) 
(figure 7). The toxicokinetic parameters are summarized in table 3 (83). 
 
Figure 7: Mean plasma concentrations of BZP (on the left) and its hydroxylated metabolites (on the right) 
over a 24h period after a single oral administration of 200 mg BZP (n=7 healthy males) (83). 
 
Table 3: Human toxicokinetic parameters for BZP, 4-OH-BZP and 3-OH-BZP (83). 
 Human toxicokinetic study 
Parameter BZP 4-OH BZP 3-OH BZP 
cmax  (ng/mL) 262 7 13 
tmax (min) 75 60 75 
AUC (min.ng/mL) 212,000 1,940 6,600 
 Absorption half-life (min) 6.2 -- -- 
Elimination half-life (t1/2) (h) 5.5 -- -- 
Cl/F (L/h) 99 -- -- 
 Cl/F, clearance reported as clearance/bioavailability 
Part I: General introduction 
27 
 
Urine analysis showed that approximately 6% (12 mg) of the total dose of BZP was 
eliminated in an unconjugated form and the unconjugated forms of 4-OH-BZP and 3-OH-
BZP only represented 0.11% of the total dose. According to mass spectra, it was 
suggested the formation of two conjugated metabolites, O-sulfate BZP and N-sulfate BZP. 
Thus, whereas in animals the conjugation with the glucuronide appears to be the main 
conjugation pathway, in humans the conjugation with sulfate appears to be, at least, 
prevalent as conjugates with the glucuronide were not detected either in plasma or urine 
samples. After the enzymatic hydrolysis the total amount of 4-OH-BZP and 3-OH-BZP 
greatly increased, and it was calculated that the O-sulfate conjugate represent about 51% 
of the excreted BZP and N-sulfate conjugate about 30% (figure 8). Furthermore, following 
enzymatic hydrolysis, the calculated total amount of BZP excreted only represented 
approximately 12.25% (24 mg) of the total dose which might be due to a low oral 
bioavailability, strong tissue or protein binding or even to the existence of other excretion 
routes (83).  
 
Figure 8: Total amount of BZP, 3-OH-BZP and 4-OH-BZP in 24h neat urine (on the left) and enzyme 
hydrolised urine (on the right) samples (83). 
 
1.2.5.4. Metabolic Interactions 
Besides pharmacodynamic interactions that may occur with other drugs that interfere 
with the neurotransmission of monoamines (such as, MDMA, cocaine, and amphetamine) 
and result in severe toxic reactions (38), metabolic interactions may also be involved in 
such effects. 
CYP is one of most important enzymatic systems being involved in the metabolization 
of a wide variety of endogenous and exogenous compounds and, in addition, is subjected 
to enzymatic induction and inhibition by many of its substrates (17, 38, 90). The ability of 
BZP to inhibit the metabolism of different selective substrates of different CYP 
isoenzymes (CYP 2D6, 1A2, 3A4, 2C9, and 2C19) was investigated in two recent studies 
using human liver microsomes assays. From the isoenzymes under study, BZP just did 
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not inhibit CYP 2C19 metabolism and for the remaining isoenzymes the inhibitory effect 
ranged in the following order: CYP 1A2> CYP 2C9> CYP 2D6> CYP 3A4. Thus, at least 
theoretically, BZP demonstrates potential for influencing the metabolism of several 
compounds co-administered with it and which are substrates of these isoenzymes (86, 
90). 
The metabolic interactions between BZP and TFMPP were studied as these 
piperazines were commonly used in combination. The results of in vitro and in vivo studies 
showed that TFMPP is metabolized by the same CYP isoenzymes involved in BZP 
metabolism (CYP 2D6, 3A4 and 1A2) (23, 86, 90), and when co-incubated (1:1, 200 μM) 
with human liver microsomes these compounds significantly and reciprocally inhibited 
each other metabolism. In fact, TFMPP inhibited the BZP metabolism in about 60% and 
BZP inhibited the TFMPP metabolism in approximately 91% (23, 86).  
In vivo studies, in rats (Wistar), shown that when co-administered (1:1, 2 mg/kg) 
interfere with each other metabolism, with BZP and TFMPP achieving higher plasma 
concentrations when administered in combination (figure 9). Furthermore, significant 
differences in the toxicokinetic parameters of TFMPP were observed after the co-
administration of these substances, which has not been observed with BZP (table 4). 
 
Figure 9: (A) BZP and (B) TFMPP concentration-time plasmatic profile after isolated or combined 
administration of BZP and TFMPP (2mg/kg, i.p.) (89). 
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Table 4: Toxicokinetic parameters (mean±SD, n=3) for BZP and TFMPP in rats (Wistar) when administered 
alone and in combination (89). 
Parameters 
 
Sole administration Co-administration 
BZP (2 mg/kg) TFMPP (2 mg/kg) BZP (2 mg/kg) TFMPP (2 mg/kg) 
k (min
-1
) 0.0037±0.0016 0.0061±0.0039 0.0034±0.0010 0.0047±0.0039 
t1/2 (min) 219±108 147±78 222±82 237±216 
V (L) 5.1±2.1 2.0±1.3 4.6±2.7 1.2±o.34 
Cl (L/min) 0.017±0.0038 0.009±0.001 0.014±0.0059 0.005±0.002 
AUC0-360 (min.mg/mL) 22±5.1 51±17 27±11 71±13 
 
In vivo studies, in humans, also shown that BZP (100 mg) and TFMPP (30 mg) 
interfere with each other metabolism, what was visible particularly with regard to the 
formations of their hydroxylated metabolites. In fact, in all urine and plasma samples 3-
OH-BZP and 4-OH-TFMPP (the main metabolites) were not detected and it was 
suggested that this may be due to CYP 2D6 inhibition (91). Alterations in the formation of 
the metabolites were not assessed in the animal study described previously but have not, 
however, been reproduced in animals when these two compounds were co-administered 
to Sprague-Dawley rats, demonstrating once more the discrepancy between human and 
animal BZP metabolism (87). Besides the absence of its main metabolite, there were also 
noted other changes in the toxicokinetics of TFMPP that are summarized in table 5. 
Furthermore, it was observed an increased amount of conjugates for both substances 
and, in the case of BZP, an increased formation of 4-OH-BZP, which suggests that, 
despite the absence of the main metabolites, the renal clearance of both drugs was not 
affected due to the formation of alternative metabolites (namely, N-sulfate BZP and N-
glucuronide TFMPP). Lastly, even using smaller doses when combined, the peak 
plasmatic concentrations were higher which may account for the synergism observed, in 
rats, in the release of monoamines when these substances were administered together 
(91). 
 
 
 
Part I: General introduction 
30 
 
Table 5: Toxicokinetic parameters (approximated values) for BZP and TFMPP in humans when administered 
alone or in combination (91). 
Parameters 
Sole administration Co-administration 
BZP (200 mg) TFMPP (60 mg) BZP (100 mg) TFMPP (30 mg) 
Absorption half-life (min) 6 24.6 6 13 
Cmáx (ng/mL) 262 24 295 28 
tmáx 75 90 60 75 
t1/2 (h) 5.5 
1
st
 phase - 2 
2
nd
 phase - 6 
4 2 
 
Considering now all this information, particularly the fact that CYP 2D6 is not one of the 
main CYP isoenzymes involved in BZP metabolism, is inhibited by this substance and the 
extend of conjugation in BZP metabolism, it is expected that polymorphisms in enzymes 
involved in the conjugation reactions (particularly in the conjugation with sulfates) have a 
greater clinical and toxicological significance than polymorphisms in CYP isoenzymes. 
 
1.2.6. Analysis 
A number of methods have been described for the analysis of BZP, its metabolites and 
other piperazines, from screening tests (colorimetric tests and immunoassays) to 
chromatographic techniques (gas chromatography (GC) and liquid chromatography (LC)) 
coupled to mass spectrometry (MS), the two main techniques employed to detect and 
quantify these compounds in different matrices.  
With respect to BZP, besides the parent drug those most commonly detected in 
forensic analyzes are the hydroxylated metabolites (3-OH-BZP and 4-OH-BZP). In fact, as 
they are the main metabolites formed, according to in vivo studies, and their plasmatic 
and urinary peaks are obtained after BZP peaks, the detection of these compounds during 
analysis allows higher sensitivity and to increase the detection window (84). 
 
1.2.6.1. Screening tests 
Colorimetric tests and immunoassays are commonly used to rapidly detect drugs in 
biological samples and seized materials (18). While immunoassays are based on more 
specific reactions (antigen-antibody reactions), colorimetric assays are less specific and 
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sensitive as they depend only on the presence of specific functional groups in the 
molecule rather than the molecule as a whole, thus the occurrence of false positive and 
negative results may occur more easily (10, 92). 
There has been described cross-reactivity with commercially available urine 
immunoassays tests available for the detection of amphetamines, namely Roche 
Abuscreen Online® Amphetamine, Dade-Behring Syva® Emit® II Plus Amphetamine (14),  
Abott® TDx Amphetamine/Methamphetamine II (71), and EMIT® d.a.u.® Amphetamines 
(19).  
BZP as well as other piperazines have also been analysed using colour tests widely 
used by drug enforcement investigators, such as Simon’s, Marquis, X-Checker® and 
Dragendorff, and results were similar to those obtained with other stimulants like 
amphetamines (93). 
 
1.2.6.2. Chromatographic Techniques  
As referred previously, chromatographic techniques (namely, LC and GC) are the most 
extensively used for the identification and quantification of BZP and its metabolites in 
different biological samples (hair, blood, plasma, serum, and urine) (table 6). Normally 
these separation techniques are coupled with mass spectrometry but other detection 
techniques have been also described, such as diode array detection (DAD) (94, 95), 
fluorescence (89), and ultraviolet (19). The different LC-MS and GC-MS analytical 
protocols published differ mainly in the method employed for sample preparation 
(hydrolysis of conjugates, analyte extraction and derivatization procedure), internal 
standards used and specific characteristics of the chromatographic analysis. The 
hydrolysis of conjugates, particularly important when performing metabolism studies in 
urine samples, was performed either by acid hydrolysis (71) or, more frequently, 
enzymatic hydrolysis (96). For analyte extraction some authors employed liquid-liquid 
extraction (LLE) (14, 71, 97, 98), or solid-phase extraction (SPE) techniques (89, 96, 99).   
A number of methods have been developed to allow the simultaneous detection of 
several drugs of abuse in different biological samples (16, 98, 100-102) as well several 
piperazine-based stimulants (94, 99) thus, presenting an added value in forensic 
toxicology. 
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Table 6: Review of the analytical methods for qualitative and quantitative analysis of BZP and metabolites. 
Analytes 
 
Sample 
Sample 
preparation 
Derivatization Internal standard 
LOD 
(ng/mL) 
LLOQ 
(ng/mL) 
Method 
BZP, TFMPP, 
oMeOPP, mMeOPP, 
oMePP, mMePP (19) 
A2 capsules 
LLE with tert-butyl 
methyl ether after 
alkalinization with 
KOH 
TFFA and ethyl acetate 
(1:1), 30 min at 65ºC 
Ephedrine NS NS GC-MS 
BZP BZP, TFMPP, 
oMeOPP, mMeOPP, 
oMePP, mMePP (19) 
A2 capsules 
LLE with tert-butyl 
methyl ether after 
alkalinization with 
KOH 
 Ephedrine NS NS GC/NPD 
BZP, benzylamine, N-
benzylethylenediamine, 
3-OH-BZP, 4-OH-BZP, 
4-OH-3-OCH3 (71) 
Human and rat 
urine 
Enzymatic 
hydrolysis (37ºC for 
12 h) and LLE with 
a mixture of 
dichloromethane-
isopropanol-ethyl 
acetate (1:1:3; 
v/v/v) 
Acetylation: acetic 
anhydride-pyridine (1:1), 
10 min at 440 W 
Trifluoroacetylation: 
TFFA and ethyl acetate 
(1:1), 5 min at 400 W 
Heptafluorobutyrylation: 
HFBA, 5 min at 400 W 
Methylation: 
diazomethane in diethyl 
ether, 15 min at room 
temperature  
 NS NS GC-MS 
Amphetamine derived 
designer drugs, BZP, 
MDBP, TFMPP, 
mCPP, and MeOPP 
(16) 
Human plasma 
Mixed-mode SPE 
(HCX) and elution 
with a mixture of 
methanol-aqueous 
ammonia (98:2) 
HFBA, 5 min at 440 Volts 
AM-d5, MA- d5, MDA- 
d5, MDMA- d5, MDEA- 
d5 and pTP 
NS 5  GC-MS 
Amphetamine derived 
designer drugs, 
cathione, 2C-B, BZP, 
among others (98) 
Human blood, 
serum, oral fluid, 
and urine  
Extraction with an 
alkaline buffer 
HFBA 
(extraction and 
derivatization in a single 
step) 
Methylmexiletine 
25 (blood); 20 
(oral fluid); 
200 (urine) 
5-10 (oral fluid) 
NS for the other 
samples 
GC-MS 
BZP, TFMPP, 4-
TFMPP, 3-OH-BZP 
and 4-OH-BZP (96) 
Rat urine 
Enzymatic 
hydrolysis (37 º C, 
12 h) 
SPE (OASIS HLB): 
elution with 
methanol 
TFAA and ethyl acetate  
(1 h at 60 ºC) 
pCPP 
20 (BZP) 
500 (3-OH-
BZP and 4-
OH-BZP)  
(SIM mode) 
NS GC-MS 
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BZP, TFMPP, 4-
TFMPP, 3-OH-BZP 
and 4-OH-BZP (96) 
Rat urine 
Enzymatic 
hydrolysis (37ºC, 
12 h) 
SPE (OASIS HLB): 
elution with 
methanol 
 pCPP 
0.2-1  
(SIM mode) 
NS LC-MS 
BZP and TFMPP(14)  Human urine 
LLE with n-butyl 
chloride after urine 
alkalinization 
 CPP 100 100 LC-MS 
BZP and TFMPP (69) 
Equine plasma 
(validation) 
Human blood, 
plasma and urine 
LLE with 1-
chlorobutane 
 norfenfluramine NS NS HPLC-DAD 
BZP and TFMPP (69) 
Equine plasma 
(method 
validation) 
Human blood, 
plasma and urine 
LLE with 1-
chlorobutane 
 norfenfluramine 
312.5 (BZP) 
20 (TFMPP) 
500 (BZP) 
31.25 (TFMPP) 
LC-MS 
Several doping agents 
including BZP (101) 
Human urine 
Centrifugation and 
dilution with water 
(1:1) 
 
Methyltestosterone 
Nalorphine 
mefruside 
screening screening UHPLC-MS 
BZP, TFMPP, 4-
TFMPP, 3-OH-BZP, 
and 4-OH-BZP (15) 
Human plasma 
Enzymatic 
hydrolysis (37 ºC, 
12 h) 
Deproteinization 
(ZnSO4 and 
methanol) and 
centrifugation 
  NS 5 LC-MS 
Several designer drugs 
including BZP (102) 
Human urine 
Dilution of urine 
with mobile phase 
(1:4) 
 
AM-d5, MDA- d5, 
MDMA- d5, MDEA- d5  
< 10 (BZP) < 30 (BZP)  LC-MS/MS 
Opioides, cocaines, 
amphetamines and 
other stimulants 
including BZP (100)  
Human blood 
Mixed-mode SPE 
elution with 5% 
ammonium 
hydroxide in ethyl 
acetate:methanol 
 
Several deuterated 
analogues 
NS NS LC-MS 
TFMPP and BZP (89) Rat plasma 
DIB-labeling  
SPE (Bond Elute 
C18) elution with 
acetonitrile 
  
0.9 (BZP) 
4.6 (TFMPP) 
3 (BZP) 
15.2 (TFMPP) 
HPLC-FL 
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BZP, TFMPP, MeOPP 
and mCPP (94) 
Human urine 
MEPS: elution with 
5% ammonium 
hydroxide in 
methanol 
 oCPP 
1000 (BZP 
and TFMPP) 
50 (MeOPP 
and mCPP) 
1000 HPLC-DAD 
2C-B, 4-bromo-2,5-dimethoxyphenetylamine; 4-CPP, 1-(4-chlorophenyl)piperazine; 4-MTA, 4-methylthioamphetamine; AM- amphetamine; DIB-Cl, 4-(4,5-diphenyl-1H-imidazol-
2-yl)benzoyl chloride; FL, fluorescence; GC-MS-, gas chromatography – mass spectrometry; GC/NPD, gas chromatography with nitrogen phosphorous detector; HFBA, 
heptafluorobutyric anhydride; HPLC-DAD, high-performance liquid chromatography-diode-array ultra-violet detection; KOH, potassium hydroxide; LC-MS, liquid 
chromatography-mass spectrometry; LLE- liquid-liquid extraction; LLOQ- lower limit of quantification; LOD, limit of detection; MA, methamphetamine; MDA, 3,4-
methylenedioxyamphetamine; MDEA, methylenedioxyethylamphetamine; MDMA, 3,4-methylenedioxymethamphetamine; MEPS, microextraction in packed sorbent; NS, not 
specified; oCPP, 1-(3-chlorophenyl)piperazine; oMePP, 1-(4-methylphenyl)piperazine; PMA, para-methoxyamphetamine;  pMePP, 1-(2-methylphenyl)piperazine; pTP, 1-(4-
tolyl)piperazine; SIM, selected ion monitoring; TFAA- trifluoroacetic anhydride; UHPLC-MS, ultra-high performance liquid chromatography-mass spectrometry; W, Watts; 
ZnSO4, zinc sulfate. 
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SCOPE AND OBJECTIVES OF THE THESIS 
 
Information about the disposition of one exogenous compound in the organism is 
important to understand its toxicity and/or pharmacology. With regard to BZP 
toxicokinetics, there are very few studies describing its metabolism and, in particular, its 
disposition which seems particularly important as preliminary and unplublished works 
report its nephrotoxicity and hepatoxicity in cell culture studies. Also, the preferential 
accumulation of its metabolites (4-OH-BZP and 3-OH-BZP) in the liver and kidneys of rats 
have also been reported. Furthermore, the published studies point to discrepances in the 
disposition between human and animals (Sprague-Dawley rats), namely for the main 
metabolite and conjugates formed. On the other hand, there are no available studies 
evaluating the disposition of other identified metabolites or elimination routes besides 
urine.  
Several chromatographic methods have been described in literature, however, those 
used in the few published toxicokinetic studies, besides BZP, only evaluated those that 
are considered their main metabolites (4-OH-BZP and 3-OH-BZP). 
The aim of this thesis is therefore contribute, to a better understanding of the 
toxicokinetics of BZP, throughout the development and validation of a GC-MS assay that 
enables the simultaneous quantification of BZP and all metabolites (benzilamine, 
piperazine, N-benzylethylenediamine, 3-OH-BZP, 4-OH-BZP and 4-OH-3-OCH3-BZP). 
The method was optimized for derivatization, extraction and chromatographic separation, 
and then validated for selectivity, sensitivity, precision and accuracy in human plasma. 
Then, the applicability of the method was evaluated in plasma samples collected from 
mice (male Charles-River CD1 mice) included in a pilot toxicokinetics study, after a single 
i.p. administration of the drug (20 mg/kg and 50 mg/kg). The developed method may be 
also applied for the investigation of both forensic and clinical toxicological cases of BZP 
poisoning. 
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1.  Material and methods 
1.1. Reagents and Standards 
Methanol (HPLC grade) was purchased from Fisher Chemical. Ethyl acetate (LC-MS 
grade), acetonitrile (HPLC grade), ammonium hydroxide (NH4OH) (25%), hydrochloric 
acid (HCl) (32%), and sodium acetate trihydrate were obtained from Merck Co 
(Darmstadt, Germany). Trifluoroacetic anhydride (TFAA) was obtained from Sigma-Aldrich 
(St. Louis, Missouri). Fluka®-Analytical Benzylamine (≥99%), piperazine (99%), N-
benzylethylenediamine (97%), 1-(o-tolyl)piperazine (oTP) hydrochloride (97%), and 4-
hydroxy-3-methoxybenzylamine hydrochloride (internal standard, IS) (98%) were 
purchased from Sigma-Aldrich (St. Louis, Missouri). Benzylpiperazine dihydrochloride 
(BZP.2HCl) was kindly supplied by Chemos GmbH (Regendauf, Germany). 4-Hydroxy-
benzylpiperazine (4-OH-BZP), 3-hydroxy-benzylpiperazine (3-OH-BZP) chloride and 4-
hydroxy-3-methoxy-benzylpiperazine (4-OH-3-OCH3-BZP) were synthesized by 
REQUIMTE/CQFB, Department of Chemistry, Faculty of Science and Technology New 
University of Lisbon. For the enzymatic hydrolysis was used β-glucuronidase type HP-2 
Helix pomatia purchased from Sigma-Aldrich (St. Louis, Missouri). SPE was performed 
using Oasis MCX® SPE 1 cm3 (30 mg) columns obtained from Waters (Milford, 
Massachusetts) and the Supelco VisiprepTM SPE Vacuum Manifold from Sigma-Aldrich 
(St. Louis, Missouri). 
1.2.  Biological Specimens 
Human plasma: for the development and validation of the method, human plasma was 
kindly obtained from Hospital de São João (Porto, Portugal). Samples were prepared as 
described below. 
Animals: for the toxicokinetic study adult male CD1 mice weighing 30-36 g were 
purchased from Charles-River Laboratories (Barcelona, Spain). Mice were housed in a 
temperature and humidity controlled environment with a 12 h light-dark cycle and ad 
libitum access to food and water. All animal use and care procedures were performed 
according to the European Community guidelines for the use of experimental animals 
(Council Directive 86/609/EEC on the Protection of Animals Used for Experimental and 
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Other Scientific Purposes, 2002) (103). Mice were randomly assigned to the different 
experimental groups after a period of quarantine and acclimatization. 
 
1.3. Preparation of stock and working standard solutions 
Stock standard solutions of BZP.2HCl, piperazine, benzylamine, N-
benzylethylenediamine, 4-OH-BZP, 3-OH-BZP chloride and 4-OH-3-OCH3-BZP at 5 
mg/mL (as free bases) were prepared with methanol. A stock solution of 3-hydroxy-
benzylpiperazine chloride at 5 mg/mL was prepared with water. The stock standard 
solutions of 4-hydroxy-3-methoxybenzylamine hydrochloride and 1-(o-tolyl)piperazine 
were prepared with methanol at 1 mg/mL. A working solution of the IS at 100 μg/mL was 
prepared by proper dilution of the stock solution also in methanol. All these solutions were 
stored light protected at -20ºC. All the solutions needed for the validation were prepared 
daily by proper dilution of the stock solutions with methanol. 
The extraction solutions of HCl 0.1 N and of 5% NH4OH in methanol were prepared by 
proper dilution with water and methanol, respectively. 
For the toxicokinetic study two standard solutions of BZP.2HCl were prepared in sterile 
saline to ensure the administration of a single i.p. dose of 20 mg/kg or 50mg/kg (as free 
base) in a volume of 0.01mL/g body weight. These solutions were freshly prepared in the 
day of the experiments. 
 
 
1.4. Preparation of plasma and urine working calibrators 
Plasma working calibrators: standards of a mixture of BZP, benzylamine, N-
benzylethylenediamine, and piperazine were prepared in methanol. To plasma aliquots of 
250 μL, 10 μL of each standard was added in order to obtain the final concentrations used 
in the linearity assay. Subsequent sample preparation (centrifugation, enzymatic 
hydrolysis, extraction and derivatization) was performed as described below. 
 
1.5. Sample Preparation for gas GC-MS analysis 
Mice urine and plasma samples were divided into two aliquots; one subjected to 
enzymatic hydrolysis prior to analysis and the other devoid of hydrolysis to determine the 
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relative excretion of conjugated metabolites. Mice and human plasma (used in method 
validation) were prepared as described in figure 10. 
 
1.5.1. Enzymatic hydrolysis 
Plasma: Aliquots of 250 µL of plasma samples were transferred to a 5 mL glass tube 
with 250 µL of 0.2 M sodium acetate buffer (pH 5.2) and 25 µL of type HP-2 β-
glucuronidase from Helix pomatia. All samples were incubated at 37 ºC for 12 h to 
hydrolyze the conjugates.  
 
1.5.2. Centrifugation 
Plasma: After hydrolysis, 10 μL of IS (100 μg/mL) and 100 μL of methanol (protein 
denaturation) were added to plasma samples. Samples were vortex mixing for 30 seconds 
and then centrifugated (13,000 rpm, 10 min at 4ºC) and the supernatant solution was 
subjected to the solid phase extraction as described below. 
 
1.5.3. Solid phase extraction 
 SPE was performed using OASIS MCX® columns and a Supelco VisiprepTM SPE 
vacuum manifold. The totality of the hydrolyzed samples was loaded onto the column. 
Immediately after, 2 x 1 mL of 0.1 M HCl followed by 2 x 1 mL of methanol were applied 
onto the column and the eluates were discarded. Finally, the compounds of interest were 
eluted into a glass tube using 2 x 1 mL of a 5% NH4OH/methanol solution. Eluates were 
completely dried under a gentle stream of nitrogen. To eliminate residual water all tubes 
were left open in a desiccator with phosphorus pentoxide (P2O5) overnight. 
 
1.5.4. Trifluoroacetyl derivatization 
To the dry residue, 50 µL of ethyl acetate and 50 µL of TFAA were added. Incubation 
was performed at 70 ºC for 30 min. After cooling to room temperature the excess of 
reagent and organic solvent was removed under a gentle stream of nitrogen. The dry 
residue was re-dissolved in 25 µL of ethyl acetate and used without further preparation for 
gas chromatography-ion trap mass spectrometry (GC-IT-MS) analysis. Each sample was 
injected in triplicate. 
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In the case of urine samples, the BZP concentration was higher than 10 μg/mL (higher 
concentration in the calibration curve), and the urine derivatized extracts were injected 
both before and after a 1000 fold dilution with ethyl acetate. 
 
Figure 10: Scheme of plasma sample preparation procedure. 
 
 
 
Chapter I: Material and methods 
47 
 
1.6. Chromatographic Equipment and Conditions 
GC-MS analysis was carried out using a Varian CP-3800 gas chromatograph (USA) 
equipped with a Varian Saturn 4000 Ion Trap mass selective detector (USA) and a Saturn 
GC/MS workstation software version 6.8. A capillary column VF-5ms (30 m x 0.25 mm x 
0.25 μm) from VARIAN was employed for the separation. Helium C-60 (Gasin, Portugal), 
at a constant flow rate of 1 mL/min, was used as the carrier gas. The injection of 2 μL of 
derivatized extracts was manually done in the splitless mode at 250 ºC. The column oven 
temperature was maintained at 100 ºC for 1 min and then raised to 300 ºC at 15 ºC/min 
and hold at 300 ºC for 10 min. For the detection, the transfer line, manifold and ion trap 
temperatures were 280, 50 and 180 ºC, respectively, and the electron energy was 70eV. 
During the first 4 min, the ionization was maintained off to avoid solvent overloading. Data 
were collected from m/z 50-600 at a scan rate of 6 scan/s. The emission current was 50 
μA and the maximum ionization time was 25,000 μs, with an ionization storage level of 35 
m/z. Mass spectra acquisition was performed between 4 and 20 min after the injection of 
the sample. Full scan mode allows the detection of all ions and was used for the 
identification and quantification of compounds. The full scan chromatograms were 
reconstructed by using selected qualifier ions for each molecule which allows the 
elimination of foreign m/z from other molecules. The selected ions used for the 
quantitative measurements were: m/z 203 and m/z 134  for benzylamine; m/z 209 and m/z 
278 for piperazine; m/z 232 and m/z 345 for IS; m/z 245 and m/z 324 for N-
benzylethylenediamine; m/z 272 and m/z 175 for BZP; m/z 384 and m/z 258 for both 3-
OH-BZP and 4-OH-BZP di-derivatized; m/z 288 and m/z 148 for both 3-OH-BZP and 4-
OH-BZP monoderivatized; m/z 414 and m/z 317 for the di-derivatized form of 4-OH-3-
OCH3-BZP and m/z 318 and m/z 137 for the monoderivatized. 
The identification of each analyte in samples was made comparing the retention times 
(tr) and mass spectra (relative abundance of the ions) of the standards with those of the 
peaks obtained when injecting the samples under the same chromatographic conditions. 
 
2. Method validation 
Analytical procedures able to detect, identify and/or quantify specific compounds in 
biological samples, with accuracy and reliability, are essential in toxicology. In fact, this is 
particularly important in forensic toxicology as such results may have legal/criminal 
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implications. Thus, methods must be validated showing that they are suitable for the 
intended analytical applications (92).  
With regard to BZP, the analytical methods published are normally only used to detect 
and/or quantify BZP in combination to its main metabolites (14, 15, 96) or few other 
piperazines also used as designer drugs (89, 94, 95, 99). Nevertheless, some other 
methods also allow the identification of BZP in combination with other stimulant drugs 
being very useful in the rapid screening of biological samples with a forensic and for 
clinical purpose (16, 97, 98, 100-102). Thus, as the primary objective of this thesis is the 
study of the toxicokinetics of BZP, including the disposition of the parent drug and all its 
putative metabolites, it was necessary the development and validation of a method that 
allows the simultaneous detection and quantification of all these compounds. 
Furthermore, besides its scientific application, its potential to be useful in the area of 
clinical and forensic intoxication with BZP was also taken into consideration. The choice of 
the IS was one of the aspects that took into account its potential application as some of 
the published methods use as internal standard other piperazines also used as designer 
drugs and sometimes combined with BZP in the same preparations (14, 96). Therefore, in 
the absence of a piperazine deuterated derivative it was selected a commercially available 
compound that is not a constituent of “party pills”. 
The validation of the described method was guided by the international guiding 
principles recommended by European Medicines Agency (EMEA) (104) and by Food and 
Drug Administration (FDA) (105). The studied parameters were selectivity, linearity, limits 
of detection (LOD) and quantification (LOQ), precision and accuracy, recovery and 
stability. Those parameters were fully evaluated for BZP and the commercially available 
metabolites (benzylamine, N-benzylethylenediamine, and piperazine) not being possible 
for the synthesized metabolites (3-OH-BZP, 4-OH-BZP and 4-OH-3-OCH3-BZP) because 
the amount available was not enough and/or they were contaminated (4-OH-BZP and 4-
OH-3-OCH3-BZP) with piperazine, one of the precursors used in the synthesis. These 
compounds were only used to determine their retention time and characteristic mass 
spectra. 
2.1. Linearity study 
To evaluate the method’s linearity, human plasma calibrators were prepared at final 
concentrations of 50 ng/mL, 100 ng/mL, 500 ng/mL, 1000 ng/mL, 5000 ng/mL, and 10,000 
ng/mL for BZP and 50 ng/mL, 100 ng/mL, 500 ng/mL, 1000 ng/mL, and 5000 ng/mL for 
benzylamine, N-benzylethylenediamine, and piperazine. Along with these working 
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calibrators a blank sample (without analytes but with IS) was also analysed. Regression 
curves were obtained plotting the peak-area ratio between each analyte and the internal 
standard against analyte concentration and the method linearity evaluated by the square 
correlation coefficient (R2). Three independent calibration curves were obtained and the 
mean slopes calculated.  
2.2. Limits of detection and lower limit of quantification 
There are several approaches to determine the LOD and LOQ. In this study they were 
determined based on the signal-to-noise ratio. A signal-to-noise ratio of 3 and 10 was 
considered acceptable for estimating the LOD and LOQ, respectively, of each calibrator. 
The 50 ng/mL working calibrators were progressively diluted with blank plasma to 
determine those limits. 
2.3. Sample storage/stability 
The stability of processed samples was evaluated at three levels of concentration (500, 
1000 and 5000 ng/mL) for plasma derivatized extracts. The prepared samples were kept 
at 4 ºC during a week. The stability was evaluated comparing the signal of samples three 
and five days after being derivatized with the signal of the same freshly prepared samples. 
2.4. Precision 
Precision (inter-day and intra-day) was evaluated using plasma spiked samples by 
calculating the mean, standard deviation (SD) and coefficient of variation (CV %) of the 
obtained values.  
2.4.1. Inter-day precision 
The inter-day precision of the method was determined for the four analytes (BZP, 
benzylamine, piperazine and N-benzylethylenediamine) by the analysis, at three different 
days (day 1, 3 and 5), of three spiked samples (500, 1000 and 5000 ng/mL). 
2.4.2. Intra-day precision of the apparatus 
The intra-day precision of the apparatus (injection) was determined by analysing five 
times (five injections) one spiked sample at a concentration of 1000 ng/mL for BZP, 
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benzylamine, piperazine and N-benzylethylenediamine, on the same day by the same 
operator. 
2.4.3. Intra-day precision of the extraction 
The intra-day precision of the extraction procedure was determined by extracting, on 
the same day, five aliquots of the same spiked sample. The concentration of each aliquot 
was 1000 ng/mL of BZP, benzylamine, piperazine and N-benzylethylenediamine. 
2.5. Accuracy 
The accuracy of the method was assessed for all four analytes in samples at three 
different concentrations (500, 1000 and 5000 ng/mL) calculating the percent deviation 
between the calculated value (obtained by interpolation on the calibration curve) and the 
nominal value [accuracy (%) = (mean calculated concentration/nominal concentration) x 
100] (106). 
2.6. Extraction efficiency 
The extraction efficiency for each analyte was tested at three different concentrations 
(500, 1000 and 5000 ng/mL), using three replicates for each concentration. A 100 % 
extracting efficiency was considered for one set of samples spiked only with IS before 
SPE extraction and then the analytes were added to the elution fractions of the samples 
before evaporation to dryness (non-extracted samples). To the other set of samples both 
IS and analytes were added before SPE (extracted samples). Extraction recovery (%) was 
calculated comparing the peak area ratios of analyte to IS for extracted and non-extracted 
samples [Extraction recovery (%) = mean peak area ratio of extracted samples / mean 
peak area ratio of non-extracted samples) x 100] (107).  
2.7. Evaluation of interferences and specificity 
In order to evaluate the presence of chromatographic interferences, several blank 
plasma samples were processed (centrifugated, extracted and derivatized) and checked 
for interferences at the retention times of the studied compounds. The GC-MS 
chromatograms of spiked samples were then compared with the chromatograms obtained 
with the blank plasma samples. 
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3. Proof of applicability: toxicokinetic study in mice 
The primary objective of toxicokinetic studies is to describe the systemic exposure after 
a drug administration through the evaluation of drug’s absorption, distribution, metabolism, 
and excretion (ADME) (108, 109). These studies are important to correctly understand the 
pharmacology and toxicology of any given compound, and are performed both in vivo and 
in vitro. The in vivo studies due to ethical issues are normally performed in animals, and 
will allow the (i) validation of toxicological species, (ii) identification of the major metabolic 
pathways, (iii) assessment of drug-drug interactions, (iv) determination of the rate and 
excretion pathway(s), and (v) evaluation of the distribution of the compound and 
metabolites in the body which helps to understand their toxicity and/or pharmacological 
effects (109). Thus, toxicokinetic studies are a part of the assessment of the risk and 
safety of compounds (110). 
With regard to BZP, its toxicokinetics has already been described in humans (studies 
performed while this substance was legal in New Zealand). However, these studies only 
evaluated the plasmatic profile and clearance of BZP and its two main metabolites (3-OH-
BZP and 4-OH-BZP) alone or in combination with TFMPP (83, 91). There is also an 
animal study conducted in Sprague-Dawley rats evaluating the urinary excretion profile of 
BZP, 3-OH-BZP and 4-OH-BZP (84). These few studies showed some discrepancies 
between humans and animals namely in the main metabolite and type of conjugates 
found. Furthermore, in the literature there is a reference to an unpublished work about the 
disposition of BZP and its two main metabolites, 4-OH-BZP and 3-OH-BZP, in rats, which 
reports a disparity in plasma and tissue concentrations of this drug and the kidneys as the 
tissue with the highest concentration of the drug (87) and another reference to the in vitro 
hepatotoxicity and nephrotoxicity of BZP (88). These results highlight the need for a more 
comprehensive study on the toxicokinetics of BZP, in an animal model. 
To achieve this, the CD-1 mice was selected in an attempt to find an experimental 
model that better simulates what happens in humans, improving the reliability of the 
experiments by decreasing the error associated with the extrapolation of results due to 
interspecies variability. After a single i.p. administration of BZP, blood, urine, faeces, 
brain, lungs, liver, heart and kidneys were collected at different times in order to evaluate 
the disposition of BZP and its six metabolites. For this dissertation it was, however, only 
possible to show the applicability of the developed method to the mice plasma samples 
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3.1. Experimental design 
Animals were treated with a single 20 or 50 mg/kg i.p. dose of BZP (in saline) delivered 
through a 27-gauge needle placed into the right lower abdominal quadrant. The animals to 
be sampled at 1440 min after dosing were individually-housed in metabolic cages for 24 h 
in order to allow the collection of urine. Blank urine was obtained during the 
acclimatization period. 
To collect plasma, mice were anaesthetized with isoflurane and blood was collected 
from caudal vena cava into heparinized syringes at 15, 30, 60, 120, 240 and 1440 min 
after a dose of 20mg/kg and at 120, 420 and 1440 min after 50 mg/kg. Four mice were 
sampled at each time indicated. Whole blood samples were then transferred to Eppendorf 
microcentrifuge tubes and stored on ice until centrifuged at 13,000 g for 10 min to obtain 
plasma. Brain, heart, lungs, liver and kidneys were rapidly dissected from each mouse at 
the same times noted for blood sampling, rinsed with saline kept on ice, dried on filter 
paper, weighed, and then frozen at -80ºC. Plasma and tissues from mice killed 5 min after 
delivery of vehicle (saline) served as controls. 
Plasma, tissue and urine samples were stored at -80°C until further analysis. 
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1. Method development 
1.1. Sample Preparation 
The analytical process consists of several steps that, in general, tend to enhance its 
sensitivity and specificity, and the selection of the different techniques used will be 
dependent on the purpose of the analysis, type of sample(s), compounds of interest, 
expected concentrations and other aspects, such as the time and equipment available 
(92). Sample preparation is of main concern during an analytical process as it allows the 
elimination of matrix effects and interfering compounds enhancing method specificity and 
selectivity, concentration of analytes enhancing sensitivity and the improvement of the 
analytical system performance (92, 111). Sample preparation may include protein 
denaturation, addition of internal standard(s), extraction/removal of interfering compounds, 
derivatization to improve chromatographic and/or detection properties, hydrolysis of 
conjugates, among other steps. However, every analytical procedure should be as simple 
as possible in order to maximize reliability and reproducibility besides minimization of time 
consumption and costs (92). 
1.1.1. Protein denaturation 
In order to decrease the complexity of plasma samples and interferences after column 
extraction, protein denaturation is a procedure frequently used, followed by centrifugation 
and supernatant collection. Several methods may be employed namely acid precipitation, 
mixtures of zinc sulfate:methanol and methanol. Compared to acid precipitation, 
deproteinization using methanol (as used) or a mixture of zinc sulfate plus methanol is 
preferred as provides a cleaner sample without causing significant alterations on pH that 
may affect analytes stability (92). 
 
1.1.2. Cleavage of conjugates 
Particularly with respect to urine samples, hydrolysis of conjugates before extraction 
and GC/MS analysis is necessary as, contrary to LC/MS procedures, it is not possible to 
directly analyze the glucuronide and sulfate conjugates because they normally are not 
volatile. Furthermore, it has been previously described the elimination of both BZP and its 
main metabolites as conjugates both in humans (83) and animals (84). Therefore, the 
hydrolysis of conjugates is needed to evaluate the percentage of parent 
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compound/metabolites eliminated as unconjugated and the total, after hydrolysis of 
conjugates, amount of parent compound/metabolites excreted. Both acidic (71) and 
enzymatic hydrolysis (96) have been employed with respect to BZP metabolism studies. 
Acidic hydrolysis has the advantage of allowing effective and rapid hydrolysis of 
conjugates but, as in acidic protein precipitation, can cause changes or decomposition of 
pH sensitive compounds. Thus, enzymatic hydrolysis is more and more frequently 
employed despite being more expensive and time consuming (71, 92, 96). Type HP-2 β-
glucuronidase from Helix pomatia was used in the present study since it has sulfatase and 
glucuronidase activity and both sulfate and glucuronide conjugates have been described 
with respect to BZP and its metabolites. The optimization of the hydrolysis conditions was 
not performed during the present study, however, Tsutsumi et al. (2005), described that 
the hydrolysis of glucuronides and sulfates in rat urine samples after a single i.p. 
administration of 10 mg/kg BZP was completed within 6 h at 37 ºC and pH 5. Furthermore, 
to ensure the complete hydrolysis even in the presence of higher levels of conjugates, an 
incubation time of 12 h was considered sufficient under the described conditions. The 
same incubation conditions were used in a previous pharmacokinetic study in humans 
(83), and these conditions were selected to perform the present toxicokinetic study. 
 
1.1.3. Extraction 
As stated in chapter 1, for the extraction of BZP and metabolites both LLE and SPE 
procedures have been developed. Considering the aim of this study and the physical-
chemical variability of BZP and its metabolites, ranging from pure bases (BZP, piperazine, 
benzylamine and N-benzylethylenediamine) to phenolbases (hydroxylated metabolites) 
which possess some acidity due to the aromatic hydroxyl group, multiple extractions or 
the use of mixtures of solvents will be necessary when performing LLE in order to improve 
the efficiency of the extraction. Furthermore, LLE procedures usually require the 
consumption of larger volumes of solvents. On the other hand, SPE techniques used both 
hydrophilic polymers (reversed-phase OASIS® HLB columns) that allow the extraction of 
acids, bases and neutrals and mixed-mode cation-exchange reversed-phase extraction 
(OASIS® MCX columns) specially designed for the extraction of bases but enabling the 
retention of acidic and neutral drugs as well (111). Tsutsumi et al. (2005) compared the 
extraction of BZP, 3-OH-BZP and 4-OH-BZP using LLE, OASIS® MCX and OASIS® HLB 
cartridges and concluded that the extraction using OASIS® MCX gave the best extraction 
recovery (96). For these reasons OASIS® MCX columns were selected to perform this 
study.  
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The OASIS® MCX method for extraction of basic compounds is represented in figure 
11 (111). Basic compounds present in the sample are loaded either in their ionized or 
neutral form. The first washing step with HCl will allow the ionization of basic compounds 
present in the non ionized form in the sample and their stronger binding to cation-
exchange sites. Furthermore, it will allow the removal of proteins and salts and the 
conversion of acidic interfering compounds into their non ionized (non polar state) form, 
enabling their removal in the next washing step with methanol. In fact, this step will 
eliminate neutral and acid interferences. Finally, the use of a basic eluente (5% NH4OH in 
methanol) will neutralize the bases (compounds of interest) bonded to the cation-
exchange sites and their elution (112). 
 
 
 
 
 
Figure 11: OASIS
®
 MCX method for extraction of basic compounds (111). 
 
Considering this proposed method, other washing and elution conditions were 
evaluated for BZP, piperazine, benzylamine, N-benzylethylenediamine, and IS. This 
evaluation could not be performed in time for the hydroxylated metabolites. Thus, it was 
also evaluated the extraction recovery using a solution of 0.5 N HCl and a solution of 15% 
NH4OH in methanol. With regards to the concentration of the HCl washing solution, it was 
observed that increasing the concentration of the HCl washing solution, the loss of 
piperazine increased, regardless the NH4OH solution used (figure 12). 
Loading sample 
Wash 1 
2 x 1mL HCl 0.1 N 
 
Wash 2 
2 x 1mL methanol 
 
Elution 
2 x 1mL 5% ammonium 
hydroxide in methanol 
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Figure 12: Full scan chromatograms of three plasma samples with the same concentration of the four 
analytes, 50,000 ng/mL, extracted with different solutions. 
The first one (A) represents a sample washed with a solution of 0.5N HCl and eluted with 5% NH4OH in 
methanol; the middle chromatogram (B) represents a sample washed with a 0.5 N HCl solution and eluted 
with 15% NH4OH in methanol; and the last one (C) a sample washed with 0.1 N HCl and eluted with 5% 
NH4OH in methanol. The blue arrow indicates the piperazine peak. 
 
This result was proved by calculation. In fact, the relative extraction recovery (%) for all 
the alternative extractive procedures compared to the “standard procedure” (0.1 N HCl 
and 5% NH4OH in methanol) was always lower than 100% [relative extraction recovery = 
(mean by alternative procedure/mean by standard procedure) x 100] (table 7). Based on 
these results and previous work by Tsutsumi et al. (2005) using a similar extractive 
procedure the “standard” conditions were chosen to perform this study. 
A 
B 
C 
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Table 7: Mean relative extraction recoveries (%) for BZP, N-benzylethylenediamine (NBED), benzylamine and 
piperazine. 
 Relative extraction recovery (%) 
Extraction conditions BZP/IS NBED/IS Benzylamine/IS Piperazine/IS 
(1)
1 
41.48 37.84 41.79 2.50 
(2)
2 
46.57 37.71 42.35 2.82 
(3)
3 
65.47 10.60 49.70 62.29 
1
 - 0.5 N HCl and 5% NH4OH in methanol 
2
 - 0.5 N HCl and 15% NH4OH in methanol 
3
 - 0.1 N HCl and 15% NH4OH in methanol 
 
Besides the optimization of the volume, pH and ionic strength of both washing and 
elution solvents it is also important to control their flow rate in order to increase the 
reproducibility of the process. In fact, this can affect the retention and elution of both 
compounds of interest and interferences, affecting the recovery efficiency and cleanup of 
the samples. For these reasons, the flow rate was kept at approximately 1 mL/min. 
 
1.1.4. Derivatization procedure 
In order to perform a GC analysis it is necessary that the compounds of interest be 
volatile and stable at the high temperatures required for the analysis. However, some 
analytes are not directly suitable to GC analysis due to its poor volatility and/or thermal 
stability and, in these cases, chemical derivatization is necessary. Derivatization can also 
be performed to enhance the chromatographic efficiency (peak resolution and separation) 
or even increase detectability. With regard to GC analysis, the replacement of active 
hydrogen in polar functional groups such as –COOH, -OH, -NH, and –SH, that affect the 
volatility, thermal stability and tendency to interact with column, can be accomplished 
through three basic types of derivatization reactions: silylation, acylation and alkylation 
(113-116).  
According to the available studies, acylation has been the most widely used technique 
for the derivatization of BZP and its metabolites, both using TFAA (19, 84, 96) or acetic 
anhydride (19, 71). Furthermore, acyl derivatives tend to direct the fragmentation pattern 
of the compounds, providing useful structural information about the initial compound by 
losing the acyl groups (113).  In fact, acylation showed to increase the stability of 
piperazine compounds and peak resolution, decrease retention times and enhance the 
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MS detection (19). Furthermore, the acyl group can react with highly polar amino, hydroxyl 
and thiol groups (113), being very popular in forensic and clinical toxicology  (96) for the 
confirmation of common drugs of abuse by GC-MS, such as methamphetamine (117). 
TFAA is the most volatile and reactive of the anhydrides and, additionally, no acid 
byproducts are formed during the derivatization decreasing the damage of the column 
(113, 117). The general reaction mechanism is illustrated in figure 13. 
 
Figure 13: General trifluoroacetylation mechanism with TFAA to obtain the O-TFA, N-TFA and S-TFA 
derivatives (117). 
 
In order to improve the efficiency of the derivatization procedure it was necessary to 
optimize the derivatization conditions namely the temperature and time of reaction. Once 
again, this optimization was only performed for BZP, IS, piperazine, N-
benzylethylenediamine and benzylamine. Instead of altering the time of reaction (fixed at 
30 min), two different volumes of TFAA were used (50 and 100 μL) and two reaction 
temperatures (60 and 70 ºC). Based on the obtained results (table 8 and figure 14) 50 μL 
of TFA, 70 ºC and 30 min were selected for the derivatization reaction. 
 
Table 8: Response (peak of analyte/peak of IS) under different derivatization conditions. 
 Derivatization study 
TFAA volume/ TºC BZP/IS NBED*/IS Benzylamine/IS Piperazine/IS 
50 μL / 60 ºC 3.94±0.46E-02 2.25±0.07E-02 5.13±0.17E-02 7.78±1.36E-02 
100 μL / 60 ºC 4.16±0.22E-02 2.05±0.21E-02 4.89±0.14E-02 1.05±0.14E-01 
50 μL / 70 ºC 4.05±0.35E-02 2.91±0.02E-02 4.83±0.20E-02 1.46±0.009E-01 
100 μL / 70 ºC 4.05±0.34E-02 2.43±0.49E-02 4.49±0.47E-02 1.18±0.006E-01 
 
The results presented are the mean±SD of three independent assays. 
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Figure 14: GC-MS response (mean peak area of analyte/mean peak area IS) of plasma samples spiked with 
of BZP, N-benzylethylenediamine (NBED), benzylamine (BA) and piperazine (P) at 500 ng/mL under different 
derivatization conditions (volume of TFAA and temperature) with time of reaction fixed at 30 min. For each set 
of conditions three independent assays were made.  
 
The derivatization of 3-OH-BZP, 4-OH-BZP and 4-OH-3-OCH3-BZP apparently may 
result in the formation of two different trifluoroacetyl derivatives instead of one unique 
derivative for each compound, mono-TFA derivatives and bis-N,O-TFA derivatives, 
according to chromatogram and mass spectra (figures 15-17).  
Other derivatizing reagents have been employed in order to analyze piperazines by 
GC, mainly trimethylsilylation (99). However, this reagent was not considered. In fact, 
considering that fluorinated acyl groups can be used to increase retention times as they 
increase the molecular weight (113), it is expected that, using trimetylsylilation the 
retention times of both benzylamine and piperazine derivatives would be even smaller 
than the derivatives of these compounds using TFAA. 
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Figure 15: Full scan and reconstructed full scan GC-MS chromatogram with selected m/z ions of a standard 
solution of 4-OH-BZP after derivatization with EI mass spectra of the mono-TFA derivative (spectrum 1A) and 
bis-TFA derivative (Spectrum 2A). The m/z selected were m/z= 288 for the mono-TFA derivative and m/z= 
384 for the bis-TFA derivative. 
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Figure 16: Full scan and reconstructed full scan GC-MS chromatogram with selected m/z ions of a standard 
solution of 3-OH-BZP after derivatization with EI mass spectra of the mono-TFA derivative (spectrum 1A) and 
bis-TFA derivative (Spectrum 2A). The m/z selected were m/z= 288 for the mono-TFA derivative and m/z= 
384 for the bis-TFA derivative. 
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Figure 17: Full scan and reconstructed full scan chromatogram with selected m/z ions of a standard solution 
of 3-OCH3-4-OH-BZP after derivatization with EI mass spectra of the mono-TFA derivative (spectrum 1A) and 
bis-TFA derivative (Spectrum 2A). The m/z selected were m/z= 318 for the mono-TFA derivative and m/z= 
414 for the bis-TFA derivative. 
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The formation of two trifluoroacetyl derivatives observed in this study appeared to be 
dependent on the volume of TFAA, as the ratio between the peak area of the bis-N,O-TFA 
derivatives and mono-TFA derivatives seems to increase when the volume of TFAA 
increases and all the other reaction conditions are kept constant (temperature and time of 
reaction). Thus, it is logical to assume that this is dependent on the metabolite 
concentration and, in this case, it is important to safeguard that the formation of both 
derivatives from 4-OH-BZP, 3-OH-BZP and 4-OH-3-OCH3 was observed at 
concentrations of 250 μg/mL in methanol and not in the biological matrix. Thus, possible 
losses of analytes during the sample preparation as the consumption of TFA by interfering 
compounds present in the matrix (plasma) and collected in the extract were not 
considered. However, considering an unpublished work by Chou et al. (2008), 
concentrations of such a magnitude (250 μg/mL) are not expected. In fact, the highest 
concentration found was of about 600 ng/mL after a single i.p. dose of 1 mg/kg (87). In 
this work doses 20 to 50 times higher were used but, considering a constant metabolic 
rate, such high concentrations (250 μg/mL) are not expected. Nevertheless, Tsutsumi et 
al. (2005) during the development of a GC-MS method to the simultaneous detection of 
BZP, 3-OH-BZP and 4-OH-BZP had already reported low reproducibility for the TFA 
derivatization for the hydroxylated metabolites, even using higher time of reaction (1 h) 
and TFA volume (200 μL) (96). Hence, the eventual formation of such derivatives was 
considered and their fragmentation pattern is also presented (figures 18 - 28). 
In this study it was also evaluated the possibility of performing GC-MS analysis without 
the derivatization step, but it resulted in the loss of piperazine peak and longer analysis 
time (due to the low volatility of the compounds) so this was no longer considered. With 
regard to the hydroxylated metabolites, the analysis without derivatization was not 
evaluated, however due to their high molecular weight and presence of the polar hydroxyl 
groups, it is expected that the GC-MS analysis without any chemical derivatization would 
not be suitable as well. 
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Figure 18: EI mass spectra of BZP N-TFA and proposed fragmentation pattern. 
 
 
Figure 19: EI mass spectra of piperazine N, N-TFA and proposed fragmentation pattern. 
 
 
 
Figure 20: EI mass spectra of benzylamine N-TFA and proposed fragmentation pattern. 
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Figure 21: EI mass spectra of N-benzylethylenediamine N-TFA and proposed fragmentation pattern. 
 
 
Figure 22: EI mass spectra of 3-OH-BZP N,O-TFA and proposed fragmentation pattern. 
 
 
Figure 23: EI mass spectra of 3-OH-BZP N-TFA and proposed fragmentation pattern. 
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Figure 24: EI mass spectra of 4-OH-BZP N,O-TFA and proposed fragmentation pattern. 
 
 
 
Figure 25: EI mass spectra of 4-OH-BZP N-TFA and proposed fragmentation pattern. 
 
 
Figure 26: EI mass spectra of 3-OCH3-4-OH-BZP N,O-TFA and proposed fragmentation pattern. 
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Figure 27: EI mass spectra of 3-OCH3-4-OH-BZP N-TFA and proposed fragmentation pattern. 
 
 
Figure 28: EI mass spectra of IS N,O-TFA and proposed fragmentation pattern. 
 
1.2. IS selection and suitability 
The use of IS helps to reduce the impact of systematic errors that affect the accuracy and 
reproducibility, thus conferring greater reliability to obtained results, being a good practice 
in chromatographic analysis. Considering its use, IS should ideally meet some 
requirements, such as: (i) similar physical and chemical properties to the analyte(s) to 
behave similar to them during sample preparation and analysis; (ii) similar detector 
response to the analyte(s); (iii) do not co-elute with analyte(s) and increase the analysis 
time; and (iv) be stable both in solution and during analysis. In some cases, for example, 
when the analysis of both parent drug and its metabolites is required, as their 
characteristics may differ from each other, more than one internal standard may be used. 
The deuterated analogues of the compounds are increasingly preferred as are those with 
a more similar behavior to analyte(s), despite being more expensive and, for some 
compounds, not yet available (92). With regard to piperazine-like stimulants, the use of 
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deuterated analogues begins to be reported in literature, for example TFMPP-d4 and BZP-
d7 (97, 118). However, mCPP, pCPP and oCPP were the most used as internal standards 
in the quantitative studies available (14, 94-96, 119). Being the aims of this study to 
develop a sensitive method suitable to be used in clinical and forensic analysis, the IS 
selected should not be a constituent of “party pills”. For that same reason, oTP was 
evaluated as IS. oTP has the same molecular weight of BZP (176.26 g/mol) and, once 
derivatized, its molecular ion (M+) has the same m/z as BZP (m/z=272). Furthermore, oTP 
chromatographic peak did not resolved with BZP (figure 29) and oTP was not considered 
any further in this analysis. Thus, another compound, 4-hydroxy-3-methoxybenzylamine, 
was evaluated as internal standard. This compound showed to have similar behavior for 
the extraction from plasma and derivatization procedure, and its retention time was 
adequate. Furthermore, it is also suitable for the simultaneous analysis of other 
piperazines (TFMPP, MeOPP and PP) (unpublished). 
With respect to urine samples, it was observed some lack of reproducibility in the 
recovery of IS, possibly due, at least in part, to pH differences between plasma and urine 
samples. For these reason, the validation of the method in urine was not performed in 
time. However, it is important to note that even in the absence of internal standardization it 
was observed linearity for BZP, N-benzylethylenediamine, piperazine and benzylamine. 
Chapter II: Results and discussion 
71 
 
 
Figure 29: Reconstructed full scan chromatogram of (A) BZP and (B) o-tolylpiperazine and respective mass 
spectra (1 and 2). The selected m/z ions were m/z 272 and m/z 175 for both compounds. 
 
 
A 
B 
1 
2 
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1.3. Gas chromatography separation and MS quantitation 
During the evaluation of the GC conditions (injector temperature and oven temperature 
program), three particular requirements should be guaranteed: the absence of co-eluted 
peaks, good resolution of chromatographic peaks, and an adequate time of analysis. With 
respect to the GC conditions selected for the determination of BZP and metabolites, in 
general, well resolved peaks were obtained eluting in less than 12 min (considering the 
possible formation of the mono-TFA derivatives). For piperazine and benzylamine, the first 
two compounds to be eluted from the column, the resolution was not as good as for the 
other compounds because their retention times are close. However, even decreasing the 
initial oven temperature (from 100 to 80 ºC) the separation was not improved (RT of 
piperazine altered from 4.64 min to 7.83 min; RT of benzylamine altered from 4.48 min to 
7.5 min) and resulted in longer retention times for all analytes.  
The full scan was reconstructed with selected m/z ions and used for the quantification. 
The ions (m/z) to be monitored for each analyte were selected taking into consideration 
their relative abundance and uniqueness (specificity) as it will help to enhance sensitivity 
decreasing the background. Ideally, more than one m/z that represent characteristic 
molecular fragments should be selected as it is associated with higher signals, including 
preferentially the M+. Thus, it was preferred m/z who presented the best compromise 
between their sensitivity (peak area) and specificity (signal-to-noise ratio) (table 9).  
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Table 9: Retention times and selected ions (m/z) used for the identification and quantification of the analytes. 
Compound tr (min) Selected ions (m/z) 
Benzylamine 4.48 203; 134 
Piperazine 4.64 209; 278  
Internal standard 7.04 232; 345 
N-benzylethylenediamine 7.90 245; 324 
Benzylpiperazine 8.45 272; 175 
3-hydroxy-benzylpiperazine.2TFA 
3-hydroxy-benzylpiperazine.TFA  
9.22 
10.59 
384; 258 
288;148 
4-hydroxybenzylpiperazine.2TFA 
4-hydroxy-benzylpiperazine.TFA 
9.47 
10.54 
384;258 
288;148 
3-methoxy-4-hydroxy-benzylpiperazine .2TFA 
3- methoxy-4-hydroxy-benzylpiperazine .TFA 
10.50 
11.09 
414; 317 
318;137 
 
2. Method validation 
2.1. Linearity study 
The linearity of the method was established spiking human plasma samples in the 
range of 0-10,000 ng/mL with BZP (six calibrators, three replicates) and 0-5,000 ng/mL 
(five calibrators, three replicates) for benzylamine, piperazine and N-
benzylethylenediamine. Along with each calibration curve, a zero blank human plasma 
sample with IS was also analysed. Calibration curves were obtained plotting the peak 
area ratio between each analyte and the IS against the analyte concentration. From all the 
analytes, BZP showed the lowest linearity (R2=0.9796). In fact it seems to show lower 
linearity for higher concentrations as in the concentration range 0-5,000 ng/mL the R2 was 
higher than 0.99 (table 10). 
For the hydroxylated metabolites, the linearity was not evaluated as they were 
contaminated. 
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Table 10: Calibration curves for BZP, benzylamine, piperazine and N-benzylethylenediamine (NBED) in 
plasma (n=3). Values presented correspond to mean±(SD). 
 Linearity study 
 Equation (y=mx+b) Range (ng/mL) R
2 
BZP 
y= 1.27x10
-4
 (±6.43x10
-5
)x + 4.06x10
-2 
(±2.89x10
-2
) 
y= 1.63x 10
-4
 (±1.18x10
-4
)x + 1.66x10
-2
 (±6.4x10
-3
) 
0-10,000 
0-5,000 
0.9796 
0.9912 
Benzylamine y= 1.97x10
-4
 (±1.05x10
-4
)x + 1.97x10
-2 
(±1.34x10
-2
) 0-5,000 0.9878 
Piperazine y= 4x10
-4
 (±2.65x10
-4
)x – 3x10
-3
 (±1.21x10
-2
) 0-5,000 0.9989 
N-BED y= 2.67x10
-4
 (±1.15x10
-4
)x + 8.467x10
-3 
(±2.90x10
-3
) 0-5,000 0.997 
 
2.2. Sensitivity 
The LOD and LOQ for each compound were established using the corresponding 
selected m/z as this procedure enhances the sensitivity comparatively to the Full scan 
method (table 11). 
 
Table 11: LOD and LOQ values in ng/mL for BZP, benzylamine, piperazine and N-benzylethylenediamine 
(NBED) in plasma. 
 Sensitivity study 
 SIM-ITMS
 
 LOD (ng/mL) LOQ (ng/mL) 
BZP 5.0 20 
Benzylamine 5.0 20 
Piperazine 5.0 20 
N-BED 2.0 7.5 
 
2.3. Precision 
Precision was expressed as CV% [CV%= (SD/mean) x 100]. This GC-IT-MS method 
showed satisfactory inter- and intra-day precision as the CV% never exceeded 15%, as 
recommended (105). 
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2.3.1. Inter-day precision of the method 
The results obtained for human plasma at three levels of concentration within the linear 
range of the assay are presented in table 12. The obtained CV% was always inferior to 
15% as recommended. 
 
Table 12: Inter-day precision of the method for the determination of BZP, N-benzylethylenediamine (NBED), 
piperazine and benzylamine (n=3). 
 Inter-day precision of the method (%) 
Concentration (ng/mL) BZP NBED Benzylamine Piperazine
 
5,000 14.16 13.47 4.36 3.43 
1,000 5.66 9.73 11.89 10.01 
500 5.81 4.88 7.41 4.70 
 
2.3.2. Intra-day precision of the extraction and apparatus 
The intra-day precision of the extraction was evaluated based on five independent 
manipulations of the same spiked plasma sample (1,000 ng/mL). The CV% ranged from 
4.65% to 14.68%. 
The intra-day precision of the apparatus (manual injection) was determined after five 
injections of the same derivatized extract of plasma (1000 ng/mL). The obtained results of 
CV% ranged from 3.97% to 8.48% (table 13). 
 
Table 13: Intra-day precision of the extraction method and apparatus for BZP, N-benzylethylenediamine 
(NBED), benzylamine and piperazine at a concentration of 1,000 ng/mL. 
 Intra-day precision (%) 
 BZP NBED Benzylamine Piperazine
 
Extraction 4.65 8.19 12.57 14.68 
Apparatus 8.48 5.68 4.30 3.97 
 
2.4. Accuracy 
 For each level of concentration, three independent plasma samples were analyzed. 
The accuracy [accuracy (%) = (mean calculated concentration/nominal concentration) x 
100] of an analytical method describes the closeness of agreement between the 
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concentration value obtained with the method and the true value (theoretical value). The 
accuracy of the method ranged from 85.78% to 114.27% (table 14) which is in accordance 
to the acceptance limits for this parameter (100±15%) (104, 105). 
 
Table 14: Accuracy (%) for the determination of BZP, N-benzylethylenediamine (NBED), benzylamine, and 
piperazine (n=3). 
 Accuracy (%) 
Concentration (ng/mL) BZP NBED Benzylamine Piperazine
 
5,000 92.17 86.56 98.21 88.99 
1,000 114.27 105.32 105.26 113.57 
500 85.78 87.59 95.67 113.76 
 
2.5. Extraction efficiency 
The extraction efficiencies [Extraction efficiency (%) = (mean peak area ratio of 
extracted samples/ mean peak area ratio of non-extracted samples)x100] for plasma 
samples were determined at three different levels of concentrations and ranged from 
85.78-115.97% (table 15).  
 
Table 15: Extraction efficiencies (%) for the determination of BZP, N-benzylethylenediamine (NBED), 
benzylamine and piperazine in plasma (n=3). 
 Extraction efficiency (%) 
Concentration (ng/mL) BZP NBED Benzylamine Piperazine
 
5,000 90.86 90.01 105.25 91.23 
1,000 112.99 107.20 115.97 92.55 
500 85.78 87.59 87.45 92.12 
 
2.6. Processed sample stability 
The stability of the processed samples (derivatized extracts) was evaluated at three 
different level of concentration. Samples were kept at 4 ºC, protected from the light during 
a week, and injected just after being prepared, and 3 and 5 days after. The inter-day CV% 
were high for all the compounds and all the concentration levels under study (table 16).  
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Table 16: Inter-day coefficients of variance (CV%) from the stability of the processed plasma samples. 
 Inter-day CV% 
Concentration (ng/mL) BZP NBED Benzylamine Piperazine
 
5,000 83.84 102.13 103.81 79.48 
1,000 90.27 90.22 83.34 73.72 
500 123.24 129.05 122.39 126.24 
 
Comparing the full scan chromatograms of the different days it is visible a gradual 
decrease of the peaks of all analytes, and a more evident reduction for the IS, which 
seems to be the less stable compound (figure 30). In fact, calculating the inter-day CV% 
of all the compounds without the correction of the signal to the IS, it is lower (table 17), for 
all the compounds, than the values presented in table 16 (where the results were reported 
as the ratio of analyte peak area and IS peak area). Furthermore, the inter-day CV% was 
higher for IS. Therefore it is recommendable to avoid long waiting times from sample 
preparation, particularly after extract derivatization, until sample analysis. In fact, samples 
should be analyzed immediately after derivatization.  
 
Figure 30: Full scan IS peaks from the stability study (red chromatogram-sample just after being prepared; 
green chromatogram – processed sample after 3 days; orange chromatogram – processed sample after 5 
days). 
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Table 17: Inter-day coefficients of variance (CV%) from the stability of the processed plasma samples without 
correct the signal with IS. 
 Inter-day CV% 
Concentration (ng/mL) IS* BZP NBED Benzylamine Piperazine
 
5,000 62.13 17.68 92.82 24.15 19.17 
1,000 57.02 6.75 12.99 6.35 14.77 
500 84.37 4.49 33.81 2.28 19.14 
*The concentration of IS was always the same and the CV% was calculated considering the variation of the IS 
signal in the samples at 5,000, 1,000 and 500 ng/mL used for the other analytes. 
 
2.7. Selectivity 
Several plasma extracts were analysed in order to evaluate the presence of 
chromatographic interfering compounds and no interference peaks were observed neither 
in the retention time of the analytes or in the IS and selected ions. 
 
3. Proof of applicability: toxicokinetic study in mice 
This method was applied to two plasma samples obtained from mice blood 120 and 
1440 min after a single i.p. administration of 50 mg/kg BZP processed and analysed as 
described in Chapter I. Plasma working calibrators prepared in the same day of the 
samples were used to obtain linear regression curves used to calculate the 
concentrations. The results obtained are described in table 18.   
Table 18: Concentration of BZP and metabolites (ng/mL) in mice plasma from a pilot toxicokinetic study. 
 
Mice plasma concentrations (ng/mL) 
Time of sample 
collection (min) 
BZP BA P NBED 3-OH-BZP 4-OH-BZP 4-OH-3-OCH3-BZP 
60 1727.27 -- 79.59 17.78 -- -- -- 
60 2195.73 -- 133.74 18.93  -- -- 
120 491.51 -- -- -- -- -- -- 
120 436.06 -- -- -- -- -- -- 
BA, benzylamine; P, piperazine; NBED, N-benzylethylenediamine 
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The most referred metabolites (3-OH-BZP and 4-OH-BZP) were not detected in the 
samples analysed. However, these were both detected (87) 30 and 60 min after a single 
i.p. administration of 1mg/kg to Sprague-Dawley rats, being the concentrations below 20 
ng/mL for 3-OH-BZP and 100 ng/mL for 4-OH-BZP (work not published). Thus, taking into 
consideration the higher dose used in this pilot study it would be expected that they would 
be detected, at least in the samples collected 60 min after the administration. Therefore, 
these results may highlight intrinsic toxicokinetic differences, particularly in the metabolism 
but also in the distribution and excretion, between the two animal models, rat and mouse. 
On the other hand, as metabolism is substrate concentration-dependent (120), the BZP 
metabolic pathways may differ between the different concentrations obtained after the two 
different doses tested. However, the correct interpretation of these results is not possible 
since these metabolites were not included in the validation of the method and may also 
show inabilities of the method itself, particularly on the sensitivity. Furthermore, no other 
studies that explore the plasma toxicokinetic of BZP and metabolites are available that 
allow the comparison and interpretation of these results.  
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Several methods have been published that enable the detection and quantification of 
BZP alone or in combination with its metabolites and other psychoactive drugs, mainly 
chromatographic methods. However, methods allowing the simultaneous detection and 
quantification of BZP and all its postulated metabolites (piperazine, benzylamine, N-
benzylethylenediamine, 3-OH-BZP, 4-OH-BZP and 4-OH-3-OCH3-BZP) are scarce. 
A reproducible, precise, sensitive and accurate GC-MS method has been developed 
and validated to detect and quantify BZP and some of the suggested metabolites 
(benzylamine, piperazine and N-benzylethylenediamine). Despite the validation was not 
performed for the hydroxylated metabolites, this method demonstrated selectivity and 
ability to resolve all the compounds (BZP, benzylamine, piperazine and N-
benzylethylenediamine, 3-OH-BZP, 4-OH-BZP and 4-OH-3-OCH3-BZP) in a total time run 
of 24 min. For BZP, benzylamine, N-benzylethylenediamine and piperazine the method is 
linear between 0 - 5,000 ng/mL (R2> 0.99, except for benzylamine, which is 0.9878) and 
the limits of detection (LOD) and quantification (LOQ) range between 2 – 5 ng/mL and 7.5 
– 20 ng/mL, respectively. The precision, inter- and intra-day (CV% between 3.43 and 
14.68%), accuracy (100 ± 15%), and extraction efficiency (100 ± 20%) were considered 
acceptable.  
Since the method was developed to be subsequently applied to a toxicokinetics study 
in mice, its applicability was demonstrated when it was applied to real mice plasma 
samples. However, further validation and possibly optimization needs to be made in order 
to enhance its toxicokinetic value, namely the validation for all the metabolites and in other 
biological matrices that will be included in the toxicokinetic study (urine and tissues).  
This method also showed some drawbacks, namely with respect to sample 
preparation. In fact, sample preparation is time-consuming, which together with the fact 
that the derivatized extract is ressuspended in a small volume, restricts its automatization 
and robustness. However, with further improvements its toxicological value and 
application will be enhanced, even because no other method that enables the 
simultaneous quantification of these seven compounds using a single internal standard, is 
currently described in literature. 
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